biopharma strategy action annual report asdon leave zhen jin research scientist kai pharmaceuticals south san francisco compare tissue sample cardio vascular disease collaboration bristolmyer squibb lead compound collaboration novel investigational medica tion emergency room treatment acute heart attack compound phase iib clinical development grant fast track status food drug administration potential treat lifethreatening disease address unmet medical need nextgeneration biopharma leader bristolmyers squibb commit help patient prevail disease complement enhance internal capability suite innovative alliance partnership acquisition string pearl strategy collaboration kai strategy include seven major transaction complete date august cover bristolmyers squibb scientist wallingford connecticut examine plate screening drug candidate disease target contain onemillionth liter particular compound s barely plenty advanced highspeed robotic technol ogy use plate screen million compound time tiny well plate breakthrough medication cancer hivaid cardiovas cular disease alzheimer illness biopharma aboutbiopharma strategy action stockholder bristolmyer squibb emerge strong lean effective enterprise well position continue deliver innovative medicine help patient prevail fight disease year global economic upheaval productivity transformation initiative continue industry challenge throw company announce december expand july track keep sight train vision represent ongoing longterm companywide effort lay december reset cost base fundamentally change way nextgeneration biopharma leader work quick agile profitable execute transformative change maximize near track achieve total billion term growth improve company earning annual productivity cost saving avoidance base wave initiative announce december financial perspective target billion cost saving avoidance punctuate win lead percent sale growth second wave announce july target billion year solid growth broad additional billion base geographically product productivity effort set motion cascade drive plavix abilify virology franchise action build momentum fast new product orencia sprycel competitive touching area business total net sale continue operation culture strategy team division worldwide billion compare billion embrace advanced selfsustaine improve net fully dilute earning share ment ensure great shareholder value come continue operation year long term cent ve recast global operating model well continue track project suit vision focus biopharma company good nearterm growth rate industry resource reallocate prioritize percent compound annual growth rate nongaap valuable opportunity partnership thirdparty earning share continue operation manufacturer help maximize asset base rebase continue rationalize mature brand portfolio convatec wound care business sell consolidate global supply network simplify august geographic footprint implement efficient gotomarket model well resource management general administrative function closely tie sale earning growth simplify standardize case improve gross margin reflect new approach source process service improve global expense source practice way manage cash flow shift business portfolio strong cash balance put heart biopharma excellent position oncology compound preclinical strategy medicine investment innovation clinical development meaningful hope patient critical future program discovery physician bring value biopharma company year ago shareholder customer area alzheimer disease take decisive step medicine disease hepatitis c unmet medical ensure robust future bio change ve need huge grow demon logic medicine specialty drug business portfolio expense mean strate proof confidence focus asset completely free focus invest key compound ve captain massive cleanly medicine pharmaceutical therapeutic area deliver execute reallocation resource segment company account new compound exploratory monetize nonpharma asset percent net sale development discovery peripheral strategy make invest core proud expand ben research development process business engage new efit bring patient efficient partnership alliance deepen exist portfolio prepare expertise capability offering likelihood generic brand nurture strong partnership certain select therapeutic area competition plavix year expand capability august complete extremely proud product partnership sale medical imaging continue play critical role historic strength bristolmyer business convatec wound medical regimen cardiovascular squibb continue central care business gross proceed disease patient worldwide biopharma philosophy billion abilify secondlarg product latestage product strategic announce initial public remarkable growth rate partnership large phar offer mead johnson nutrition percent reflect value maceutical company help complete early develop additional indication balance risk reach patient retain percent stake major depressive disorder freeing resource room mead johnson poise con patient tell investment core tinue derive steady source income feel like development commercialization growth vital infant research development capability currently engage pediatric nutrition business effort continue lead steady broad partnership time believe access pub flow milestone latestage key product include plavix avapro lic investment help mead johnson pipeline asset continue advance abilify atripla grow independent company submit onglyza latestage medicine include nonpharma divestiture diabete medicine develop onglyza dapagliflozin apixaban sale percent stake e jointly astrazeneca bolster early midstage imclone contribute total cash united states europe japan research pipeline form balance approximately billion receive approval erbitux select alliance biotech partner end ability complete sprycel january series transaction transaction amass continue advance string pearl liquidity time access cash earlystage pipeline fastgrow new pearl help bol increasingly fleeting speak lead e oncology pipeline example ster pipeline balance ership foresight make significant cancer portfolio bristolmyers squibb well company medicine marketplace build cluster expertise bristolmyers squibb annual reportkey therapeutic area great unmet medical need include cardiovascular disease solid tumor bristolmyer squibb hematologic malignancy hepatitis emerge c alzheimer disease strong leaner exciting work gain ground follow path effective enterprise acquisition adnexus year transaction acquisi tion kosan bioscience global collaboration exelixis pdl biopharma kai pharmaceuticals early add global collaboration agreement zymo genetic collaboration james cornelius chairman chief executive officer agreement nissan chemical industry teijin pharma instance transaction management team importantly ve position ve build string m pleased ve solidify self strong partner biotech pearl require learn act worldclass management team circle gain high profile quickly decisively opportunitie good ve encounter year demonstrate ability nurture emerge rapidly reprioritiz working health care industry innovation asset talent ing resource spot basis cross expand management worth note ve pursue functional swat team prepare council include brian daniels string pearl rigor turn dime call lead global development restraint bid research new disease area evaluate medical affair carlo de notariste imclone meet counteroffer unfamiliar asset structure trans fani lead technical operation deem expensive act action accordingly global support function discipline withdraw offer small lean scale batrice cazala lead global decision ultimately result accelerate shift agile commercialization europe approximately billion proceed cando culture instance set mc meet weekly focal share sell earn topdown tone accomplish point key operational issue respect investment community eliminate cor discussion resolution porate aviation group relocate early addi biopharma culture shift executive office space manhat tional change management underpin ultimate success tan modest accommodation team governance structure bet transition biopharma com time embrac ter align biopharma company pany cultural shift transforming e employeedriven initiative establish executive committee approach daily work speed decisionmake clarify meet asneede basis deal announce new line accountability critical strategic issue strategy say need hold accountability face company join come agile entrepreneurial central tenet culture sig committee lamberto andreotti accountable achieve goal nale importance maintain elliott sigal jeanmarc huet year ve measure prog high level ethical conduct time lamberto ress area rapid pace compliance take responsi appoint president chief change accomplishment bility individual decision operating officer elect pipeline disease area biopharma leader future bristolmyers cancer squibb dedicate discover develop innovative medicine address unmet atherosclerosisthrombosis medical need key disease area believe well help patient prevail diabete compound research program discovery early stage research compound exploratory development preclinical early obesity clinical development development compound investigational drug laterstage clinical psychiatric disorder development submit regulatory agency approval finally medicine market alzheimer disease product development drive current future growth undergo continued clinical development determine additional indica hepatitis tion formulation benefit patient hivaid investigational compound research program represent chart bar discovery exploratory development immunology development market product development include rheumatoid arthritis solid organ transplant rejection pipeline chart january member companys board director heritage include active role global health jeanmarc promote executive vice president care leader year observe decade chief financial officer give responsibility company foundation commit million oversee strategy productivity addition finance address epidemic hivaids africa time investment grow million biopharma leadership future large public private pledge cause vastly improve enterprise look future december commit million optimism confidence year foundation continue good work ve bring tough challenge industry global secure future africa philanthropic initia economy large know wellprepare tive world success uncertain age course great leadership opportunity result transformation inspire employee work hard admirable enterprise internal day ability connect million patient external measure fifth annual survey barron world patient grateful world mostrespecte company bristol mission business extend enhance human life myers squibb include time year rank th base variety attribute includ e strong management sound business strategy ethical practice financial performance james cornelius proud biopharma chairman chief executive officer future retain important aspect march bristolmyers squibb annual reportfinancial review management discussion analysis financial condition result operation quantitative qualitative disclosure market risk consolidated financial statement note consolidated financial statement report management control procedure report independent register public accounting firm fiveyear financial summary bristolmyer squibb management discussion analysis financial condition result operation executive summary company bristolmyer squibb company refer bristolmyer squibb bms company global biopharmaceutical nutritional product company mission extend enhance human life provide high quality pharmaceutical nutritional product company engage discovery development licensing manufacturing marketing distribution sale pharmaceutical nutritional product company reportable segmentspharmaceutical nutritional pharmaceutical segment consist global pharmaceuticalbiotechnology international consumer medicine business account approximately company net sale nutritional segment consist mead johnson nutrition company mead johnson primarily infant formula children nutritional business account approximately company net sale financial highlight follow table summary operating activity year end december dollar million net sale net earning continue operation net earning discontinue operation net earning net cashdebt net sale company net sale continue operation increase plavix clopidogrel bisulfate abilify aripiprazole continue drive worldwide sale growth sale increase respectively significant contribution sale growth provide key product include orencia abatacept sprycel dasatinib hiv hepatitis portfolio net earning continue operation increase net earning continue operation attribute increase sale growth favorability gross margin portion attribute favorable product mix cost saving avoidance result company productivity transformation initiative pti million aftertax gain relate tender company share imclone systems inc imclone significant impact net earning continue operation specify item discuss expensesgain net earning discontinue operation company complete divestiture bristolmyers squibb medical imaging medical imaging business gross purchase price million result aftertax loss million convatec business gross purchase price approximately billion result aftertax gain billion result medical imaging convatec business relate gain loss include discontinued operation year present net cashdebt net cashdebt position december improve proceed billion divestiture convatec medical imaging business proceed billion sale imclone share cash generate operating activity billion adequate fund dividend payment billion capital expenditure payment million annual report business environment company conduct business primarily pharmaceuticalbiotechnology industry highly competitive subject numerous government regulation competitive factor significantly affect company sale product include product efficacy safety price costeffectiveness marketing effectiveness product label quality control quality assurance manufacturing operation research development new product successfully compete business health care industry company demonstrate product offer medical benefit cost advantage currently company new product introduction compete product market therapeutic category addition potential competition new product competitor introduce future company manufacture brand product price high generic product generic competition company lead challenge globally pharmaceuticalbiotechnology industry majority innovative product commercial value usually realize period product market exclusivity product lose exclusivity long protect patent subject new compete product form generic brand exclusivity loss company lose major portion product sale short period time currently generic version biological product approve united states law law change future absence new legislation food drug administration fda take step allow generic version certain biologic competitor seek approval biological product file safety efficacy datum address challenge biologic manufacturing involve complex process costly traditional pharmaceutical operation internationally health care industry subject governmentimposed regulation authorize price price control continue impact company sale congress state legislature consider number proposal enact law result major change current health care system nationally state level drive budget concern medicaid access reimbursement restriction implement state propose addition medicare prescription drug improvement modernization act provide outpatient prescription drug coverage senior citizen legislation modest favorable impact company result increase number senior drug coverage time continue potential negative impact pharmaceutical business result pricing pressure control market outside company operate environment governmentmandate costcontainment program regulatory body group exert downward pressure pricing pricing freedom limited united kingdom uk instance operation profit control plan germany operation reference price system company face significant delay market access new product year elapse drug approval new medicine available country growth manage care organization mcos play large role competition surround health care industry mco seek reduce health care expenditure participant make volume purchase enter longterm contract negotiate discount pharmaceutical provider market potential create large pool participant marketing prescription drug mcos important company strategy company compete inclusion mco formulary company generally successful major product include company believe development manage care industry include continued consolidation continue generally downward pressure price pharmaceuticalbiotechnology production process complex highly regulate vary widely product product shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval biologic manufacturing involve complex process traditional pharmaceutical operation biologic important company product portfolio company continue arrangement thirdparty manufacturer substantial investment increase internal capacity produce biologic commercial scale investment new state oftheart manufacturing facility production biologic devens massachusetts construction begin company maintain competitive position market strive uphold position dependent success discover develop innovative costeffective product serve unmet medical need company expand pti activity order achieve additional saving order reduce cost streamline operation rationalize global manufacturing productive competitive biopharmaceutical company company subsidiary subject number significant pende lawsuit claim proceeding investigation possible time reasonably assess final outcome investigation litigation additional discussion legal matter note legal proceeding contingency bristolmyer squibb strategy company multiyear strategy transformation nextgeneration biopharma company strategy encompass aspect geographie business yield substantial cost saving cost avoidance increase company financial flexibility advantage attractive market opportunity arise managing cost company overall strategy transition nextgeneration biopharma company focus deliver present commitment maximize nearterm growth opportunity improve earning base company announce pti design create total billion annual productivity saving cost avoidance wave announce december target billion saving cost avoidance second wave announce july target additional billion saving cost avoidance company continue focus development biopharmaceutical business maintain growth invest research development new product pipeline company continue invest key growth product include specialty biologic medicine cardiovascular metabolic drug company seek reallocate resource continue string pearl strategy enable strategic transaction acquisition kosan biosciences inc kosan strategic alliance global codevelopment cocommercialization agreement exelixis inc exelixis global collaboration agreement zymogenetics inc zymogenetic enter company continue pursue partnership expand collaborative arrangement biopharmaceutical company continue enter strategic alliance party order obtain right develop manufacture market andor sell pharmaceutical product right own party company continue maximize value noncore business company complete divestiture convatec medical imaging business company sell mature brand business locate egypt new product pipeline development sprycel january company announce approval sprycel japan ixempra december company announce new datum study ixempra ixabepilone plus capecitabine compare capecitabine include prespecifie sub set analysis demonstrate significant increase progression free survival patient triple negative breast cancer november committee medicinal product human use chmp europe issue negative opinion marketing authorization application ixempra treatment patient metastatic breast cancer company request reexamination case currently consideration chmp exelixis december company announce global collaboration exelixis cover novel molecule cancer associate development program exelixis xl small molecule inhibitor meet vegfr ret xl currently phase iii development medullary thyroid cancer exelixis xl small molecule inhibitor raf kinase currently phase development treatment patient advance solid tumor malignancy agreement company receive development commercialization right program dapagliflozin december company astrazeneca plc astrazeneca announce expansion worldwide collaboration include development commercialization dapagliflozin japan dapagliflozin investigational drug joint development company currently study phase iii clinical trial country include assess efficacy safety oncedaily treatment type diabete erbitux january company marketing partner imclone whollyowne subsidiary eli lilly company lilly announce company withdraw eventually resubmit application fda broaden use erbitux cetuximab include firstline treatment patient advance nonsmall cell lung cancer combination platinum base chemotherapy cisplatinvinorelbine october fda accept file priority review supplemental biologic license application sbla broaden indication erbitux include use combination platinumbase chemotherapy firstline treatment patient recurrent metastatic squamous cell carcinoma head neck annual report october publication study result show metastatic colorectal cancer mcrc patient wildtype normal kra tumor treat erbitux plus well supportive care bsc statistically significant increase overall survival progressionfree survival compare treat bsc specifically patient tumor normal mutant negative kras gene achieve near twofold improvement overall survival progressionfree survival patient treat bsc patient mutate kras tumor significant difference overall progressionfree survival treat erbitux plus bsc treat bsc company fda discussion possible label change relate study september announcement year datum show significant improvement overall survival patient locally regionally advanced head neck cancer extreme study publish new england journal medicine show erbitux improve survival firstline recurrent andor metastatic head neck cancer july erbitux receive marketing approval japan treatment patient advance recurrent colorectal cancer annual meeting american society clinical oncology asco landmark phase iii study flex show addition erbitux platinumbase chemotherapy significantly increase overall survival firstline treatment patient advance nonsmall cell lung cancer compare platinumbase chemotherapy abilify supplemental new drug application abilify approve fda february acute treatment manic mixed episode associate certain pediatric patient age bipolar disorder fda approval receive new abilify indication pediatric bipolar age maintenance therapy pediatric schizophrenia age maintenance therapy addon treatment lithium valproate acute treatment bipolar disorder pediatric age adult patient european commission authorize marketing abilify march treatment moderate severe manic episode bipolar disorder prevention new manic episode patient experience predominantly manic episode manic episode respond abilify treatment orencia october company announce result month study show orencia compare placebo pbo significantly improve multiple aspect healthrelate quality life physical psychosocial pain sleep quality juvenile idiopathic arthritis jia patient age year result study look safety efficacy orencia children jia fail previous treatment methotrexate mtx biologics october company announce result phase iiib study adult patient early moderatetosevere erosive rheumatoid arthritis ra receive previous mtx treatment study show orencia combination mtx significantly patient achieve disease activity score creactive proteindefine remission compare mtx plus pbo safety profile orencia combination mtx similar mtx plus pbo quarter company file sbla fda use orencia patient early ra june new phase ii datum present european league rheumatism demonstrate orencia delay development ra people undifferentiate inflammatory arthritis april orencia approve fda treatment juvenile ra additionally label orencia revise indication mean orencia appropriate option patient moderatetosevere ra regardless prior treatment receive baraclude company announce november datum separate cohort evaluation longterm treatment baraclude entecavir associate improve liver histology include improvement fibrosis chronic hepatitis b patient histology datum present th annual meeting american association study liver disease new datum march asian pacific association study liver meeting demonstrate continue low incidence resistance baraclude nucleosidenaive patient year treatment important chronic hepatitis b patient require longterm treatment bristolmyers squibb reyataz october company announce week datum castle study patient reyatazr arm achieve undetectable viral load define human immunodeficiency virus hiv rna copiesml compare patient lopinavirr arm difference treatment arm relate discontinuation rate reyatazr arm discontinuation rate lopinavirr arm october fda approve use reyataz atazanavir sulfate milligram oncedaily boost ritonavir milligram combination therapy previously untreated treatmentnave hiv infect patient use daily reyatazritonavir hiv infect treatmentnave adult patient base week result castle study demonstrate similar antiviral efficacy reyatazritonavir twicedaily lopinavirritonavir hiv combination therapy treatmentnave hiv infect adult patient datum castle study publish august issue lancet june european approval receive expand indication reyataz mg oncedaily boost ritonavir mg combination therapy treatmentnave hiv infect patient february datum compare boost reyataz reyataz plus ritonavir lopinavirritonavir present congress retroviruse opportunistic infection apixaban september company development partner pfizer inc pfizer announce phase ii study appraise apixaban novel anticoagulant provide encourage trend suggest anticoagulation apixaban current standard care continue initial hospitalization reduce risk second heart attack stroke death primary endpoint meet phase iii study apixaban prevention venous thromboembolism vte patient undergo total knee replacement result trial necessitate change protocol ongoing apixaban study company consider study prevent vte knee surgery submit regulatory filing vte prevention second half previously communicate program direct prevention vte include european medicine evaluation agency registration study treatment vte acute coronary syndrome prevention stroke atrial fibrillation continue plan ipilimumab favorable update survival datum announce september phase ii study ipilimumab saxagliptin favorable result announce september phase iii study onglyza saxagliptin regulatory submission onglyza europe june july respectively annual scientific session american diabetes association phase iii study demonstrate saxagliptin produce significant reduction key measure glucose control treatmentnave people type diabete compare placebo elotuzumab company enter agreement pdl biopharma inc august global development commercialization elotuzumab antic antibody currently phase development multiple myeloma kai company enter agreement kai pharmaceuticals inc kai develop commercialize kais novel acute heart attack medicine kai kosan june bristolmyers squibb complete acquisition kosan biosciences inc kosan cancer therapeutic company library novel compound include hsp inhibitor cancer microtubule stabilizer additional potential neurodegenerative disease zymogenetics january company zymogenetics announce global collaboration peginterferon lambda novel type interferon currently phase ib development treatment hepatitis c relate development program plavix european committee medicinal product human use march issue positive opinion recommend approval milligram loading dose tablet plavix positive opinion ratify european commission annual report result operation follow discussion company result continue operation exclude result relate medical imaging business prior divestiture january convatec business prior divestiture august medical imaging convatec previously present component health care operating segment rename convatec operating segment subsequent medical imaging divestiture business segregate continue operation include discontinue operation period present company result operation follow change dollar million vs vs net sale earning continue operation income taxis minority interest net sale provision income taxis effective tax rate net earning continue operation net sale net sale composition change net sale follow vs vs net sale analysis change analysis change total foreign total foreign dollar million change volume price exchange change volume price exchange nonu total increase net sale primarily drive growth key pharmaceutical product describe detail increase international net sale aid weaken dollar relative certain foreign currency especially euro uk pound general company business seasonal information pharmaceutical prescriber demand reference table pharmaceutical set forth comparison change net sale estimate total prescription growth retail mail order customer certain company key pharmaceutical product new product sell pharmaceutical business nonu net sale base location customer bristolmyer squibb company net sale segment follow net sale change total net sale dollar million vs vs pharmaceutical nutritional total company recognize revenue net sale adjustment arrive net sale report consolidated statement earning adjustment refer grosstonet sale adjustment describe critical accounting policy reconciliation companys gross sale net sale significant category grosstonet sale adjustment follow year end december dollar millions gross sale grosstonet sale adjustment prime vendor chargebacks woman infant child wic rebate manage health care rebate contract discount medicaid rebate cash discount sale return adjustment total grosstonet sale adjustment net sale grosstonet adjustment primarily function gross sale activity typically correlate current sale trend case manage health care rebate contract discount medicaid rebate cash discount adjustment manage health care rebate contract discount medicaid rebate affect change sale mix contractual legislative discount rate increase manage health care rebate contract discount impact reduction reserve relate tricare retail pharmacy refund program prime vendor chargeback decrease result low sale taxol paclitaxel attribute loss exclusivity woman infant child wic rebate decrease related net impact wic contract transaction increase sale return primarily attribute increase provision pravachol pravastatin sodium drive high retail sale return previously assume loss exclusivity zerit stavudine variance sale return compare prior year attribute high provision cardiovascular nonexclusive brand discontinue commercialization tequin gatifloxacin annual report activity end balance significant category grosstonet sale adjustment follow manage health woman care rebate infant prime vendor child contract medicaid cash sale dollar million chargeback wic rebate discount rebate discount return adjustment total balance january provision relate sale current period provision relate sale prior period return payment impact foreign currency translation discontinue operation balance december provision relate sale current period provision relate sale prior period return payment impact foreign currency translation discontinue operation balance december company record grosstonet sale adjustment relate sale prior period significant item include charge sale return million million primarily result high expect return certain nonexclusive product significant revision estimate grosstonet sale adjustment pharmaceutical composition change pharmaceutical net sale follow vs vs net sale analysis change analysis change total foreign total foreign dollar million change volume price exchange change volume price exchange nonus total key pharmaceutical product contribute growth sale plavix abilify represented approximately total pharmaceutical net sale represent approximately total growth pharmaceutical sale compare prior year plavix abilify represent approximately total pharmaceutical net sale contribute approximately total growth pharmaceutical net sale growth offset decrease net sale attribute generic competition pravachol international pharmaceutical sale aid weaken dollar foreign currency compare previous period company report international net sale include copromotion sale report alliance partner sanofiaventis sanofi plavix avaproavalide irbesartanirbesartanhydrochlorothiazide continue growth bristolmyer squibb net sale key pharmaceutical product represent total pharmaceutical net sale respectively follow table detail international pharmaceutical net sale key product percentage change prior year foreign exchange impact compare prior year commentary detail reason significant variance key product provide change attributable foreign net sale change exchange dollar million vs vs vs vs cardiovascular plavix nonus total avaproavalide nonus total pravachol nonus total virology reyataz nonus total sustiva franchise total revenue nonus total baraclude nonus na total na oncology erbitux nonus total taxol nonus total sprycel nonus na total na ixempra na nonus total na affective psychiatric disorder abilify nonus total immunoscience orencia nonu na na total negative pravachol sale reflect high retail sale return previously assume change excess annual report plavix platelet aggregation inhibitor company alliance sanofi sale increase primarily attribute increase prescription demand high average selling price demand negatively affect begin quarter second quarter launch generic clopidogrel bisulfate generic distribution channel substantially deplete june estimate total prescription demand clopidogrel bisulfate brand generic increase approximately respectively estimate prescription demand brand plavix increase respectively international net sale negatively impact august launch clopidogrel alternative salt clopidogrel besylate launch germany note legal proceeding contingenciesplavix litigation discussion plavix exclusivity litigation eu avaproavalide know eu aprovelkarvea angiotensin ii receptor blocker treatment hypertension diabetic nephropathy sanofi alliance worldwide sale increase primarily attribute high average selling price offset decline overall demand total prescription demand avaproavalide decrease approximately approximately pravachol hmg coa reductase inhibitor treatment hypercholesterolemia reduce risk heart attack worldwide sale decrease attribute continued generic competition key european market market exclusivity end april eu countrie sale negatively impact high retail sale return previously assume reyataz protease inhibitor treatment hiv sale increase primarily high prescription demand respectively international sale increase primarily high demand markets europe key driver june approval frontline treatment growth international revenue attribute increase demand europe latin america sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv include sustiva efavirenz antiretroviral drug bulk efavirenz include combination therapy atripla efavirenez mg emtricitabine mgtenofovir disoproxil fumarate mg product sell joint venture gilead sciences inc gilead worldwide sale increase primarily high demand attribute successful launch atripla july eu december canada october prescription demand sustiva franchise increase approximately less extent high average selling price contribute increase net revenue baraclude oral antiviral agent treatment chronic hepatitis b worldwide sale increase primarily continued growth market particularly international market successful launch country include china february uk germany july france japan september april continue increase awareness acceptance longterm efficacy safety resistance datum evidence american association study liver disease treatment guideline recommend baraclude line treatment option erbitux monoclonal antibody design exclusively target block epidermal growth factor receptor express surface certain cancer cell multiple tumor type normal cell currently indicate use colorectal cancer head neck cancer erbitux company strategic alliance imclone sell company exclusively sale increase primarily increase demand recent indication usage treatment head neck cancer sale positively impact transition broad distribution model result high sale associate initial shipment inventory distributor bristolmyers squibb taxol anticancer agent currently sell exclusively nonus market sale decrease primarily generic competition japan sprycel oral inhibitor multiple tyrosine kinase treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib meslylate worldwide sale increase primarily high demand associate successful launch july european market begin fourth quarter high sell price continue launch russia turkey ixempra microtubule inhibitor treatment patient metastatic locally advanced breast cancer sale increase reflect launch product october abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder company strategic alliance otsuka pharmaceutical co ltd otsuka sale increase primarily attribute increase demand high average selling price prescription demand increase approximately approximately contribute prescription growth new indication certain patient bipolar disorder major depressive disorder international sale increase primarily attribute increase prescription demand sale growth aid new bipolar indication second quarter eu orencia fusion protein indicate adult patient moderate severe ra inadequate response currently available treatment mtx antitumor necrosis factor therapy sale increase primarily continued growth launch biologic product february international sale increase reflect european launch estimate prescription change datum provide annual report include information retail mail order channel reflect information channel hospital institution longterm care estimate prescription datum base nextgeneration prescription service ngps version national prescription audit provide ims health im supplier market research pharmaceutical industry describe datum provide im product im recordkeeping process estimate base im sampling procedure datum subject inherent limitation estimate base sampling include margin error company calculate estimate total prescription change base ngps datum weightedaverage basis reflect fact mail order prescription include great volume product supply compare retail prescription mail order prescription typically reflect day prescription retail prescription typically reflect day prescription calculation derive multiplying ngps mail order prescription datum factor approximate add ngps retail prescription company believe calculation estimate total prescription change base weightedaverage approach respect retail mail order channel provide superior estimate total prescription demand company use methodology internal demand forecast company continuously seeks improve quality estimate prescription change amount ultimate patientconsumer demand review methodology process calculation estimate review analysis party datum calculation company expect continue review refine methodology process calculation estimate continue review analyze party datum calculation annual report estimate endus demand follow table set forth company key pharmaceutical product sell pharmaceutical business year end december total net sale period ii change report net sale period iii estimate total prescription change retail mail order channel calculate company base ngps datum weightedaverage basis iv month inventory hand wholesale distribution channel year end december december change change month total net sale net salesa total prescription b hand dollar millions plavix avaproavalide pravacholh reyataz sustiva franchise c baraclude erbitux na na na sprycel e ixemprad f na na na abilify orencia g na na na reflect percentage change net sale dollar term b derive multiplying ngps mail order prescription datum factor approximate add ngps retail prescription c begin quarter sustiva franchise total revenue include sale sustiva revenue bulk efavirenz include combination therapy atripla change total prescription growth sustiva franchise include brand sustiva atripla prescription unit erbitux orencia ixempra parenterally administer product prescriptionlevel datum physician write prescription product e sprycel launch july f ixempra launch october g orencia launch february h negative net sale attribute high retail return previously assume change excess pursuant securities exchange commission sec consent order describe sec consent order company monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel company obligate disclose product level inventory excess month hand expect demand subject de minimis exception follow product estimate level inventory distribution channel excess month hand case company pharmaceutical product december case company international pharmaceutical nutritional product september september bufferin salicylatate drug approximately month inventory hand direct customer compare approximately month inventory hand december increase level inventory hand primarily increase inventory level china cause distributor preparation national holiday september dafalgan analgesic product sell principally europe approximately month inventory hand compare month inventory hand december previously state level inventory hand september primarily private pharmacist purchase dafalgan approximately week seasonality product september videxvidex ec antiviral product approximately month inventory hand direct customer compare month inventory hand december previously state level inventory hand primarily government purchasing pattern brazil company contractually obligate provide videxvidex ec brazilian government placement order product government term contract company control inventory level relate order bristolmyer squibb product sell exclusively wholesaler distributor company determine month hand estimate information respect inventory level product hand outmovement product provide company large wholesaler account approximately total gross sale pharmaceutical product provide company distributor factor influence company estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum represent recordkeeping process reflect estimate pharmaceutical product sell exclusively wholesaler distributor companys pharmaceutical business outside nutritional business unit world company significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely case direct customer product level inventory ultimate patientconsumer demand outmovement datum exist available company develop variety methodology calculate estimate datum include factor historical sale direct customer thirdparty market research datum relate prescription trend endus demand accordingly company rely variety method estimate direct customer product level inventory calculate month hand business unit factor affect company estimate include generic competition seasonality product direct customer purchase light price increase new product product presentation launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation nutritional composition change nutritional net sale follow vs vs net sale analysis change analysis change total foreign total foreign dollar million change volume price exchange change volume price exchange nonus total infant formula toddlerchildren nutritional represent total nutritional net sale respectively follow net sale change dollar million vs vs infant formula enfamil toddlerchildren nutritional decrease nutritional net sale primarily decrease sale infant formula increase international nutritional net sale primarily growth infant formula children nutritional increase nutritional net sale primarily increase sale infant formula international nutritional net sale increase primarily growth infant formula children nutritional annual report geographic area general company product available country world large market france spain canada china japan italy mexico germany companys sale geographic area base location entity sell product follow net sale change total net sale vs vs dollar millions united states europe middle east africa western hemisphere pacific total item previously discuss pharmaceutical item impact increase net sale europe middle east africa sale increase primarily sale growth major european market abilify sprycel hiv hepatitis portfolio addition favorable foreign exchange impact sale essentially flat sale growth major european market sprycel abilify hiv hepatitis portfolio favorable foreign exchange impact offset generic competition pravachol taxol western hemisphere country sale essentially flat minimum foreign exchange impact sale increase primarily increase sale plavix canada mexico key nutritional product avaproavalide canada favorable foreign exchange impact increase partially offset discontinued commercialization tequin pacific region sale increase primarily sale growth baraclude china japan korea key nutritional product region addition favorable foreign exchange impact respectively addition sale negatively impact increase generic competition taxol pravachol single country outside contribute company total revenue net sale france canada spain japan exceed million net sale china italy exceed million mexico million sale bristolmyer squibb expensesgain change net sale vs vs dollar million cost product sell marketing sell administrative advertising product promotion research development acquire inprocess research development provision restructure net litigation expense net gain sale product line businesse equity net income affiliate gain sale imclone share expense net total expense net change excess cost product sell improvement cost product sell percentage net sale primarily attribute favorable worldwide pharmaceutical product sale mix high pharmaceutical average selling price realize manufacture saving pti factor partially offset product material price increase cost include manufacture rationalization charge million relate implementation pti net sale compare million rationalization charge record net sale improvement cost product sell percentage sale primarily sale growth high margin product include plavix marketing selling administrative increase primarily relate million increase process standardization cost incur pti compare prior period million cost incur initial public offering mead johnson high selling expense support key product unfavorable foreign exchange impact increase primarily unfavorable impact foreign exchange high marketing expense partially offset low sale force expense decrease marketing sell administrative expense percentage net sale result increase sale growth outpace expense manage pti advertising product promotion increase primarily relate increase promotion new indication abilify increase promotion orencia increase expense international nutritional business unfavorable foreign exchange impact increase primarily relate increase spending directtocustomer advertising plavix abilify orencia expense support launch ixempra high spending new product europe unfavorable foreign exchange impact annual report research development increase primarily relate increase licensing upfront milestone payment increase spending pipeline compound unfavorable foreign exchange impact increase partially offset share codevelopment cost alliance partner astrazeneca pfizer increase primarily attribute continued investment latestage compound develop pipeline disease area address significant unmet medical need increase upfront milestone payment compare detailed increase partially offset share codevelopment cost alliance partner astrazeneca pfizer upfront milestone payment expensed research development total million pay primarily exelixis pdl biopharma inc kai charge total million pay exelixis pfizer adnexus therapeutics inc adnexu isis charge total million pay exelixis solvay global research development expense dedicated pharmaceutical product pharmaceutical net sale respectively acquire inprocess research development acquire inprocess research development cost iprd consist estimate fair value research development acquire acquisition december immediately expense acquisition date charge relate iprd acquisition kosan charge relate iprd obtain acquisition adnexus provision restructure net increase provision restructure net attribute timing implementation pti announce december expand july increase attribute charge primarily severance relate associate announcement pti december note restructure litigation expense net litigation expense relate reserve settlement principle certain pricing sale investigation partially offset insurance recovery unrelated matter positive settlement litigation matter additional information litigation matter note legal proceeding contingency gain sale product line business gain primarily attributable sale mature brand business egypt gain attribute sale bufferin excedrin brand japan asia exclude china taiwan certain oceanic country certain asset relate dermatology product gain attribute sale inventory patent intellectual property right relate dovonex additional information transaction note acquisition divestiture equity net income affiliate equity net income affiliate principally relate company international joint venture sanofi increase correlate increase international plavix sale additional information equity net income affiliate note alliance collaboration gain sale imclone share gain sale imclone share attribute company receipt approximately billion cash tender investment imclone note alliance collaboration detail bristolmyer squibb expense net component expense net follow year end december dollar million interest expense interest income ar impairment charge gainloss debt buyback termination interest rate swap agreement foreign exchange transaction gainslosse net expense net interest expense decrease primarily decrease interest rate interest income relate primarily interest earn cash cash equivalent investment marketable security decrease interest income primarily change mix company shortterm investment portfolio decrease rate return shortterm investment include treasury bill compare prior year ar impairment charge attribute company auction rate security ar addition million loss sale ar recognize include net note cash cash equivalent marketable security detail gain debt buyback attribute repurchase certain debt monetization certain interest rate swap recent appreciation value note shortterm borrowing longterm debt information foreign exchange transaction gain attribute strengthen dollar impact nonqualifye foreign exchange hedge remeasurement nonfunctional currency denominate transaction compare prior year net include income thirdparty contract manufacture certain royalty income expense debt retirement cost gain loss sale property plant equipment gain loss sale marketable security insurance recovery defer income recognize certain litigation matter convatec medical imaging net transitional service fee amortization certain upfront payment relate company alliance proceed swap termination pension curtailment note expense net information annual report year end december company record follow specify expenseincome item affect comparability result period present discussion item note alliance collaboration note restructure note acquisition divestiture note income taxis note cash cash equivalent marketable security note shortterm borrowing longterm debt note legal proceeding contingency acquire gain marketing inprocess provision sale gain year end december cost sell research research litigation product sale product restructure expense line imclone expense dollar million sell administrative development development net net business share net total productivity transformation initiative downsize streamline worldwide operation accelerate depreciation asset impairment shutdown cost pension settlementscurtailment process standardization implementation cost gain sale leaseback property termination lease contract gain sale product line business litigation settlement insurance recovery mead johnson charge product liability upfront milestone payment acquire inprocess research development asset impairment ar impairment charge loss sale debt buyback swap termination gain sale imclone share income taxis item decrease net earning continue operation bristolmyer squibb marketing acquire provision gain sale year end december cost selling research inprocess litigation product product research restructure expense line expense dollar million sell administrative development development net net business net total productivity transformation initiative downsize streamline worldwide operation accelerate depreciation asset impairment process standardization implementation cost litigation settlement insurance recovery product liability upfront milestone payment acquire inprocess research development ar impairment charge downsize streamline worldwide operation accelerate depreciation asset impairment contract termination gain sale property product line business income taxis item change estimate taxis prior year specify item decrease net earning continue operation gain sale year end december cost marketing research provision litigation product product sell restructure expense line expense dollar million sell administrative development net net business net total litigation matter pharmaceutical pricing sale litigation product liability claim damage commercial litigation insurance recovery debt retirement cost accelerate depreciation asset impairment contract termination upfront milestone payment downsize streamline worldwide operation gain sale product line business income taxis item change estimate taxis prior year specify item decrease net earning continue operation specify item present reflect segment result follow dollar million pharmaceutical nutritional total segment corporateother total include million gain sale imclone share annual report earning continue operation income taxis minority interest earning continue operation income taxis minority interest change segment net sale vs vs dollar million pharmaceutical nutritional total segment corporateother total pharmaceutical earning increase primarily increase sale plavix abilify hiv hepatitis portfolio orencia increase segment income percentage segment net sale primarily similar factor discuss analysis consolidate expense favorable product sale mix high average selling price realize manufacturing saving pti contribute reduction cost product sell percentage net sale result pti contribute reduction marketing sell administrative expense percentage net sale earning increase primarily increase plavix sale strong sale growth key product increase segment income percentage segment net sale similar reason discuss less extent pti begin nutritional earning increase primarily increase international net sale increase segment income percentage segment net sale primarily growth rate net sale exceed growth rate marketing selling administrative expense research development bad debt charge distributor insolvency factor partially offset high dairy price advertising promotion expense additional legal accounting consulting expense incur preparation initial public offering earning increase primarily growth key product decrease segment income percentage segment net sale primarily high dairy price unfavorable product mix bad debt charge distributor insolvency corporateother earning continue operation income taxis minority interest report corporateother consist dollar million corporate administrative expense stockbase compensation expense provision restructure net litigation expense net interest expense interest income ar impairment charge gain sale imclone share gain sale product line business gainloss debt buyback termination interest rate swap agreement total corporateother earning continue operation income taxis minority interest bristolmyer squibb income taxis effective income tax rate earning continue operation income taxis minority interest compared increase effective tax rate primarily high pretax income include gain sale imclone earning mix high tax jurisdiction partially offset impact low nondeductible charge acquire inprocess research development expense low ar impairment charge little tax benefit tax rate favorably impact benefit million tax relate final settlement audit internal revenue service tax rate unfavorably impact impairment company investment certain ar little tax benefit nondeductible writeoff acquire inprocess research development expense relate acquisition adnexus partially offset tax benefit million quarter favorable resolution certain tax matter internal revenue service relate deductibility litigation settlement expense foreign tax credit claim effective tax rate unfavorably impact elimination tax benefit section internal revenue code treatment provision portion certain litigation reserve nondeductible partially offset favorable tax legislation enact related tax treatment certain intercompany transaction company foreign subsidiary implementation tax planning strategy relate utilization certain charitable contribution company recognize significant defer tax asset december relate federal foreign tax credit carryforward approximately million federal research development tax credit carryforward approximately million federal charitable contribution carryforward fully utilize gain relate convatec medical imaging divestiture foreign tax credit research development tax credit carryforward expire vary amount begin foreign tax credit research development tax credit carryforward reduce derecognition fin convatec medical imaging divestiture result significant reduction foreign tax credit research development tax credit carryforward realization foreign tax credit research development tax credit carryforward dependent generating sufficient domesticsource taxable income prior expiration realization assure management believe likely defer tax asset realize minority interest minority interest primarily relate company partnership sanofi territory cover america relate plavix sale increase minority interest correspond increase sale plavix dollar millions sanofi partnership minority interest pretax income taxis minority interest net taxis financial position liquidity capital resource company continue maintain sufficient level work capital approximately billion december billion december future period company expect cash generate operation exist cash cash equivalent marketable security borrowing capital market sufficient cover cash need work capital capital expenditure company expect include investment facility increase maintain company capacity provide biologic commercial scale strategic alliance acquisition milestone payment dividend pay cash cash equivalent marketable security conversion work capital item borrowing expect fund nearterm operation outside december company obtain billion year revolve credit facility syndicate lender extendable anniversary date consent lender facility contain customary term condition include financial covenant ratio consolidated debt consolidated capital exceed end quarter company compliance covenant inception new facility borrowing outstanding revolve credit facility december february mead johnson enter year syndicate revolve credit facility agreement credit facility unsecured provide borrowing letter credit million annual report net financial asset net financial asset position december follow dollar million financial asset cash cash equivalent marketable securitiescurrent total financial asset debt shortterm borrowing include current portion longterm debt longterm debt total debt net cashdebt net cashdebt net cashdebt position december improve proceed billion divestiture convatec medical imaging business proceed billion sale imclone share cash generate operating activity billion adequate fund dividend payment billion capital expenditure payment million investment follow table summarize company carry value relate unrealized lossgain position current noncurrent marketable security include dollardenominated float rate security frs ar account available sale debt security note cash cash equivalent marketable security discussion company frs ar portfolio include related cost basis fair value investment deceber decemb er decemb er unrealize unrealized lossgain carry lossgain dollar million carry value accumulate oci value accumulate oci current available sale float rate security treasury bill total current noncurrent available sale auction rate security float rate security total noncurrent company receive million principal par primarily frs mature march temporarily reduce carrying value remain frs million million unrealized loss accumulate comprehensive income oci addition company reclassify million remain frs maturity date current asset noncurrent asset liquidity concern continue uncertainty capital market company receive million primarily connection sale ar carry value million result loss million addition million otherthantemporary impairment charge recognize include million previously determine temporary december impairment charge require analysis otherthantemporary impairment factor include severity duration decline value future prospect issuer company ability intent hold security recovery ar sell security generally back sub prime mortgage collateralize debt obligation structure credit ar remain december represent interest insurance securitization less extent structure credit uncertainty credit capital market continue market deteriorate company experience additional rating downgrade investment portfolio include frs ar company incur additional impairment bristolmyer squibb investment portfolio negatively affect company financial condition report earning company believe base company current level cash cash equivalent marketable security expect operating cash flow current lack liquidity credit capital market material impact company liquidity cash flow financial flexibility ability fund operation include dividend credit rating moodys investor service moodys longterm shortterm credit rating company currently prime respectively moodys revise longterm credit rating outlook negative stable standard poor sp longterm short term credit rating company currently respectively sps longterm credit rating remain stable outlook fitch rating fitch longterm shortterm credit rating company currently f respectively fitchs longterm credit rating remain stable outlook working capital follow discussion work capital decem ber dollar million work capital increase work capital billion december december impact proceed sale convatec business billion proceed sale imclone share billion proceed issuance note billion note million cash flow follow discussion cash flow activity year end december dollar million cash flow provide byused operating activity invest activity financing activity operate activity cash flow operating activity represent cash receipt cash disbursement relate activity company invest activity financing activity operate cash flow derive adjust net earning noncash operating item depreciation amortization impairment charge stockbase compensation charge gain loss attribute invest financing activity gain loss sale product line business change operate asset liability reflect time difference receipt payment cash associate transaction recognize result operation company operate cash flow grow consistently year end december increase net income attribute reason note mda continue directly impact operating cash flow evident net income adjust noncash operating item gain loss attribute invest financing activity amount billion billion billion amount exclude change operate asset liability discuss annual report net impact change operate asset liability discuss detail include impact change receivables inventory defer income account payable income taxis receivablepayable operating asset liability company continue maximize operate cash flow recently announce work capital initiative design continue improve work capital item directly affect change sale volume account receivable inventory account payable change operate asset result net cash inflow million impact cash inflow income tax payablereceivable million include impact receipt million tax refund include interest relate prior year foreign tax credit carryback claim cash inflow account payable million primarily attribute time vendor alliance payment cash inflow inventory million primarily attribute utilization inventory build prior year new product launch strategic build exist product launch include new indication abilify cash inflow defer income million primarily receipt upfront milestone payment alliance partner cash outflow operate asset liability million primarily net litigation relate payment current period million attribute settlement certain pricing sale litigation accrue prior period pension funding excess current year expense million increase noncurrent inventory million cash outflow account receivables million attribute increase sale change operate asset result net cash outflow million impact cash outflow account receivable million primarily attribute increase sale cash outflow foreign income taxis payable million primarily attribute tax payment include settlement payment associate tax issue irs audit cash inflow defer income million primarily receipt upfront milestone payment alliance partner include pfizer astrazeneca cash inflow operate asset liability million primarily increase accrue royalty attribute increase plavix sale increase accrue salary bonus timing payment partially offset cash outflow primarily relate litigation relate payment million settlement pricing sale litigation accrue prior period cash inflow account payable million include impact increase purchase raw material plan inventory buildup change operating asset result net cash outflow million impact cash outflow operate asset liability million primarily pay accrue rebate return primarily result exclusivity loss pravachol volume erosion highly rebated paraplatin taxol lower plavix volume reduce royalty low plavix sale addition litigation settlement accrual relate pricing sale litigation settlement primarily offset net litigation relate payment relate matter accrue prior year million cash outflow account payable million primarily low purchase pravachol raw material loss pravachol exclusivity significant reduction payable early result low payment invoice december cash inflow account receivables million primarily low plavix sale loss exclusivity pravachol bristolmyer squibb investing activity net cash provide investing activity billion include proceed divestiture convatec billion medical imaging million mature brand business egypt million proceed tender company share imclone billion proceed sale leaseback paris france facility million capital expenditure million include expenditure associate construction company biologic facility deven massachusetts acquisition kosan million net cash investing activity million include capital expenditure million acquisition adnexu million net proceed sale marketable security million proceed sale bufferin excedrin brand japan asia exclude china taiwan certain oceanic countrie dermatology product million net cash provide investing activity million include net proceed sale marketable security million proceed disposal property connection sale lease administrative facility new jersey million proceed sale product asset primarily sale asset relate dovonex million capital expenditure million milestone payment primarily relate imclone million financing activity net cash financing activity billion include dividend payment billion redemption float rate convertible senior debenture billion repayment note august million yen note million repurchase company note million net proceed issuance note million note billion net proceed termination interest rate swap agreement million net proceed stock option exercise million reflect exercise few stock option decrease average stock price compare prior period net cash financing activity billion include dividend payment billion repayment float rate bank facility billion proceed exercise stock option million net cash financing activity billion include debt payment associate early retirement note billion float rate bank facility billion dividend payment billion proceed issuance note billion euro note billion annual report dividend declare common share december company declare quarterly dividend common share indicate dividend year share dividend decision quarterly basis company board director contractual obligation payment period company contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt interest longterm debt operating lease purchase obligation standby letter creditperformance guarantee uncertain tax position longterm liability total current portion longterm debt obligation include shortterm borrowing company consolidated balance sheet december balance approximate outstanding nominal longterm debt value include estimate future interest payment shortterm longterm debt include accrue interest payable record consolidated balance sheet consist primarily accrual interest shortterm longterm debt accrual periodic cash settlement derivative net counterparty uncertainty relate timing reversal uncertain tax position shortterm uncertain tax benefit provide table include minority interest million table exclude future contribution company pension postretirement postemployment benefit plan require contribution contingent numerous factor include minimum regulatory funding requirement fund status plan uncertainty future obligation exclude table contribution international plan expect million note pension postretirement postemployment benefit detail addition company commit approximately billion potential future research development milestone payment party inlicense development program payment agreement generally payable achievement certain developmental regulatory milestone specific timing predict achievement milestone probable reasonably estimable contingency record company consolidate balance sheet discussion contractual obligation note shortterm borrowing longterm debt note financial instrument note lease note pension postretirement postemployment liabilitie sec consent order previously disclose august company enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit company quarterly report form q period end september term consent company agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice company agree consent certain measure implement include establish formal review certification process annual quarterly report file sec b establish business risk disclosure group c retain outside consultant comprehensively study help reengineer company account financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand e ensure company budget process give appropriate weight input come adequately document process bristolmyer squibb company establish companywide policy limit sale direct customer purpose comply consent policy include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis company maintain inventory management agreement imas pharmaceutical wholesaler account nearly total gross sale pharmaceutical product current term ima company large wholesaler customer provide company weekly information respect month hand productlevel inventory outmovement product wholesaler currently account approximately total gross sale pharmaceutical product inventory information receive wholesaler company internal information estimate month hand product level inventory wholesaler company estimate month hand product inventory level pharmaceutical businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast company pharmaceutical business outside nutritional business unit world company significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly company rely variety method estimate month hand product level inventory business unit company believe abovedescribe procedure provide reasonable basis ensure compliance consent recently issue accounting standard follow new accounting pronouncement critical company financial statement discuss note acounte policiesrecently issue accounting standard consider evaluated require application impact eitf issue account nonrefundable advance payment good service receive use future research development activity sfas fair value option financial asset financial liability sfas fair value measurement sfas disclosure derivative instrument hedging activity eitf issue accounting collaborative arrangement relate development commercialization intellectual property sfas noncontrolle interest consolidate financial statementsan amendment arb sfas r business combination critical accounting policy company prepare financial statement conformity accounting principle generally accept preparation financial statement conformity generally accept accounting principle gaap require use estimate assumption affect report amount asset liability include disclosure contingent asset contingent liability date financial statement report amount revenue expense report period company critical accounting policy important company financial condition result operation require difficult subjective complex judgment management application result need estimate effect matter inherently uncertain uncertainty factor surround estimate judgment preparation consolidated financial statement actual result vary estimate company believe follow discussion represent critical accounting policy management discuss company critical accounting policy audit committee board director revenue recognition company recognize revenue accordance staff accounting bulletin sab revenue recognition financial statement amend sab revenue recognition company accounting policy revenue recognition substantial impact report result rely certain estimate require difficult subjective complex judgment management company recognize revenue net grosstonet sale adjustment discuss involve significant estimate judgment title substantially risk reward ownership transfer customer generally occur date shipment annual report case new product product introduction extension exist line product company determine product similar therapeutic category company determine new product dissimilar characteristic exist product company reliably estimate expect return new product company defer recognition revenue right return long exist company develop sufficient historical experience estimate sale return discussion revenue recognition note accounting policiesrevenue recognition sale rebate return accrual grosstonet sale adjustment company follow significant category grosstonet sale adjustment prime vendor chargeback wic rebate manage health care rebate contract discount medicaid rebate cash discount sale return adjustment involve significant estimate judgment require company use information external source company account grosstonet sale adjustment accordance eitf issue accounting consideration give vendor customer include reseller vendor product sfas revenue recognition right return exist applicable net sale section reconciliation company gross sale net sale significant category grosstonet sale adjustment prime vendor chargeback company business participate prime vendor program government entity significant department defense department veteran affair party pricing product extend wholesaler list price participate entity entity purchase product wholesaler low prime vendor price wholesaler charge difference acquisition cost low prime vendor price company company account prime vendor chargeback reduce account receivable equal company estimate chargeback claim attributable sale company determines estimate prime vendor chargeback primarily base historical experience prime vendor chargeback current contract price prime vendor program company consider prime vendor payment level inventory distribution channel company claim processing time lag adjust reduction account receivable periodically quarter reflect actual experience wic rebate company nutritional business participate competitive bidding basis nutrition program sponsor state tribal government commonwealth puerto rico territory woman infant child wic program company reimburse entity difference wholesaler list price contract price eligible product company account wic rebate establish accrual equal company estimate wic rebate claim attributable sale company determines estimate wic rebate accrual primarily base historical experience wic rebate current contract price wic program company consider level inventory distribution channel new wic contract terminate wic contract change exist wic contract wic participation adjust accrual periodically quarter reflect actual experience manage health care rebate contract discount company offer rebate discount manage health care organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit addition commercial plan globally contract counterpartie hospital group purchasing organization addition company pay rebate department defense tricare retail pharmacy refund program company account manage health care rebate contract discount establish accrual equal company estimate manage health care rebate contract discount attributable sale company determine estimate manage health care rebate contract discount accrual primarily base historical experience rebate discount current contract price company consider sale performance product subject manage health care rebate contract discount level inventory distribution channel adjust accrual periodically quarter reflect actual experience bristolmyer squibb medicaid rebate company business participate state governmentmanage medicaid program certain qualify federal state government program discount rebate provide participate state local government entity discount rebate provide program include company medicaid rebate accrual consider medicaid rebate purpose discussion company account medicaid rebate establish accrual equal company estimate medicaid rebate claim attributable sale company determines estimate medicaid rebate accrual primarily base historical experience medicaid rebate expansion prospective basis participation nonmandatory aspect qualify federal state government program legal interpretation applicable law relate medicaid qualify federal state government program new information change medicaid program regulation guideline impact rebate company consider outstanding medicaid claims medicaid payment level inventory distribution channel adjust accrual periodically quarter reflect actual experience cash discount certain country company offer cash discount approximate sale price incentive prompt payment company account cash discount reduce account receivable discount company consider payment performance adjust accrual reflect actual experience sale return company account sale return accordance sfas revenue recognition right return exist establish accrual equal company estimate sale record related product expect return provision sale return million million million approximate gross sale year return establish product company determine estimate sale return accrual primarily base historical experience sale return consider factor impact sale return factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product company consider factor adjust accrual periodically quarter reflect actual experience event product recall product discontinuance company consider reason impact action adjust sale return accrual appropriate taking account historical experience estimate level inventory distribution channel product discontinuance estimate continue demand sale return accrual new product estimate primarily base historical sale return experience similar product line product similar therapeutic category limit circumstance new product extension exist line product company historical experience product similar therapeutic category company reliably estimate expect return new product company defer recognition revenue right return long exist company develop sufficient historical experience estimate sale return company consider shelf life new product determine believe adjustment sale return accrual appropriate shelf life connection new product tend short shelf life establish product company develop optimal manufacturing process new product lengthen shelf life addition high launch quantity manufacture advance launch date ensure sufficient supply exist satisfy market demand case company assess reduce shelf life estimate level inventory distribution channel project demand determine believe adjustment sale return accrual appropriate adjustment addition grosstonet sale adjustment describe company make grosstonet sale adjustment example company offer sale discount significantly nonus business offer consumer coupon rebate significantly nutritional pharmaceutical business addition number country outside include certain major european country company provide rebate government entity company generally account grosstonet adjustment establish accrual equal company estimate adjustment attributable sale company generally determine estimate accrual grosstonet sale adjustment primarily base historical experience performance commitment government entity relevant factor include estimate level inventory distribution channel adjust accrual periodically quarter reflect actual experience annual report use information external source company use information external source estimate grosstonet sale adjustment company estimate inventory wholesaler base project prescription demandbase sale product historical inventory experience company analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum companys internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital company receive information im supplier market research pharmaceutical industry use project prescription demandbase sale pharmaceutical product ims refine improve ngps projection methodology fully roll ngps version national prescription audit subscriber result newly revise volume estimate historic time period quarter company new im standard ngps version projection methodology apply ngps version datum report prescription growth market share period present annual report company continue practice combine retail mail prescription volume retailequivalent basis company use methodology internal demand forecast company use information external source identify prescription trend patient demand average selling price company estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date company receive thirdparty information retirement benefit company pension plan postretirement benefit plan account actuarial valuation management require significant subjective judgment number actuarial assumption include discount rate salary growth longterm return plan asset retirement turnover health care cost trend rate mortality rate depend assumption estimate pension postretirement benefit expense vary range outcome material effect report earning addition assumption materially affect project benefit obligation future cash funding company adopt sfas employer account define benefit pension postretirement plansan amendment fasb statement r year end december adoption accounting pronouncement result billion reduction accumulate comprehensive income stockholder equity million reduction total asset million increase total liability adoption sfas impact company result operation cash flow company key assumption calculate cost pension benefit discount rate rate compensation increase expect longterm rate return plan asset company consultation actuary evaluate key actuarial assumption assumption calculate cost pension benefit retirement turnover mortality rate base expectation actual experience appropriate determine assumption december year calculate liability information date pension expense follow year depend assumption pension expense vary range outcome material effect report earning addition assumption materially affect project benefit obligation future cash fund actual result give year differ estimate economic factor determine discount rate company use yield high quality corporate bond coincide cash flow plan estimate payout citigroup median yield curve determine discount rate plan assume rate compensation increase company determine future pension obligation reflect estimate change actual future compensation level general price level productivity seniority factor plan pension expense determine assumed discount rate assume rate compensation increase present value benefit obligation december plan determine assumed discount rate assume rate compensation increase assume discount rate determine plan pension expense reduce expense increase approximately million assumed rate compensation increase determine plan pension expense reduce expense decrease approximately million assumed discount rate determine project benefit obligation december reduce project benefit obligation increase million determine expect longterm rate return plan asset company estimate return individual asset class input external advisor company consider longterm historical return include actual performance compare benchmark similar investment bristolmyer squibb plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million detailed discussion retirement benefit note pension postretirement postemployment liability acquisition company consolidate financial statement result operation reflect acquire business completion acquisition acquire business account purchase method accounting require purchase price allocate net asset acquire respective fair value excess purchase price estimate fair value net asset acquire record goodwill amount allocate acquire iprd expense date acquisition judgment determine estimate fair value assign class asset acquire liability assume asset live materially impact result operation method determine fair value asset acquire liability assume intangible asset include iprd typically use income method method start forecast expect future net cash flow cash flow adjust present value apply appropriate discount rate reflect risk factor associate cash flow stream significant estimate assumption inherent income method method include timing project future cash flow time project cost develop iprd commercially viable product discount rate select measure risk inherent future cash flow assessment asset life cycle competitive trend impact asset include consideration technical legal regulatory economic barrier entry expect change standard practice indication address asset determine useful life intangible asset require judgment different type intangible asset different useful life example useful life right associate pharmaceutical product exclusive patent finite result amortization expense recognize result operation determinable period detailed discussion acquire inprocess research development note accounting policiesacquire inprocess research development impairment longlive asset company periodically evaluate current fact circumstance indicate carry value depreciable asset hold recoverable circumstance determine exist estimate undiscounted future cash flow produce longlived asset appropriate grouping asset compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique include discount value estimate future cash flow company report asset dispose low carrying value estimate net realizable value goodwill tested annually impairment twostep process step identify potential impairment second step measure impairment loss goodwill deem impaired carrying reporting unit goodwill exceed estimate fair value longlive asset test impairment onestep process consist comparison fair value carry value asset asset deem impaired net book value exceed estimate fair value estimate future cash flow base reasonable supportable assumption projection require management judgment change key assumption company business prospect change market condition result impairment charge impairment charge longlive asset million million million discussion impairment longlive asset note accounting policiesimpairment longlive asset goodwill intangible asset annual report equity investment company review equity investment impairment base determination decline market value investment company carry value temporary making determination company consider apb opinion equity method accounting investment common stock relate interpretation set forth factor evaluate determine loss value recognize include company ability hold investment market price market price fluctuation investment publicly trade share inability investee sustain earning capacity justify carry investment company previous investment imclone subject accounting discussion company investment imclone note alliance collaboration discussion equity investment note accounting policiesinvestment note alliance collaboration marketable security company marketable security december consist treasury bill frs ar lack availability observable market quote company investment portfolio frs ar company utilize valuation model include base expect cash flow stream collateral value include assessment counterparty credit quality default risk underlie security discount rate overall capital market liquidity valuation subject uncertainty difficult predict factor impact company valuation include change credit rating security underlie asset support security rate default underlie asset underlie collateral value discount rate counterparty risk ongoing strength quality market credit liquidity considerable judgment estimation apply valuation frs ar addition company apply judgment determine marketable security otherthantemporarily impair company typically consider severity duration decline future prospect issuer company ability intent hold security recovery otherthantemporary impairment charge relate ars million million respectively carry value ars million december credit capital market continue deteriorate uncertainty market continue market deteriorate company experience additional rating downgrade investment portfolio include ar company incur additional impairment charge discussion marketable security frs ar note fair value measurement note cash cash equivalent marketable security restructuring streamline operation rationalize manufacture facility company periodically record restructuring charge result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place actual result vary estimate adjustment reflect change estimate restructure action take prior period result increase million reduction million million discussion restructuring note accounting policiesrestructure note restructure contingency normal course business company subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability accordance sfas accounting contingency company record accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency note accounting policiescontingencie note income taxis note legal proceeding contingency bristolmyer squibb income taxis provision income taxis determine asset liability approach accounting income taxis approach defer taxis represent future tax consequence expect occur report amount asset liability recover pay provision income taxis represent income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis company asset liability adjust change tax rate tax law change enact valuation allowance record reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment company net defer tax asset billion billion december respectively net valuation allowance billion billion company recognize significant defer tax asset december relate federal foreign tax credit carryforward million federal research development tax credit carryforward million realization tax credit carryforward dependent generating sufficient domesticsource taxable income prior expiration realization assure management believe likely defer tax asset realize company establish liability possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know discussion income taxis note account policiesincome taxis note income taxis special note forwardlooke statement annual report write oral statement company make time time contain certain forwardlooking statement meaning section security act section e securities exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing company goal plan projection financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include internal external factor delay divert change year company include important factor cautionary statement include annual report company believe cause actual result differ materially forward look statement company believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date company undertake obligation release publicly revision forwardlooke statement result new information future event annual report quantitative qualitative disclosure market risk company expose market risk change currency exchange rate interest rate less extent natural gas pricing reduce risk company enter certain derivative financial instrument available costeffective basis hedge underlie economic exposure company primary net foreign currency translation exposure euro japanese yen canadian dollar chinese renminbi mexican peso manage exposure company utilize foreign currency contract subject cash flow hedge accounting treatment instrument manage consolidated basis efficiently net exposure advantage natural offset company use derivative instrument interest rate risk management strategy derivative instrument comprise principally fixedtofloate rate interest swap subject fairvalue hedge accounting treatment addition company financial instrument include derivative subject counterparty credit risk company consider overall fair value measurement derivative financial instrument speculative purpose foreign exchange risk significant portion company revenue earning expose change foreign currency rate addition company expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability order manage risk company use foreign exchange forward contract offset exposure certain asset liability earning denominate certain foreign currency foreign exchange forward contract designate hedge change fair value derivative recognize earning expense net occur addition company utilize foreign currency contract manage foreign exchange risk primarily arise certain intercompany transaction designate derivative instrument foreign currency cash flow hedge appropriate notional amount company foreign exchange derivative contract billion billion december respectively derivative majority qualify hedge future anticipate cash flow effective portion change fair value temporarily defer accumulate oci recognize earning hedge item affect earning company estimate appreciation depreciation underlie currency hedge level dollar december variable hold constant decrease million increase million respectively fair value foreign exchange forward contract hold december company expose translation risk nonus dollardenominate net asset order manage risk company use nonus dollar borrowing primarily million note million note hedge foreign currency exposure company net investment certain foreign affiliate nonus dollar borrowing designate hedge net investment effective portion foreign exchange gain loss hedge record foreign currency translation component accumulate oci additional information note financial instrument interest rate risk company use interest rate swap interest rate risk management strategy interest rate swap principally fixedtofloate rate swap designate fairvalue hedge sfas accounting derivative instrument hedging activity require interest rate swap qualify fairvalue hedge accounting underlie debt report fair value swap underlie debt revalue result million increase noncurrent asset longterm debt december swap generally hold maturity intend create appropriate balance fix float rate debt company company estimate increase decrease basis point shortterm longterm interest rate decrease increase fair value company interest rate swap million exclude effect counterparty credit risk additional information note fair value measurement note cash cash equivalent marketable security note shortterm borrowing longterm debt note financial instrument bristolmyers squibb consolidate statement earning dollar share million share datum year end december earning net sale cost product sell marketing sell administrative advertising product promotion research development acquire inprocess research development provision restructure net litigation expense net gain sale product line businesse equity net income affiliate gain sale imclone share expense net total expense net earning continue operation income taxis minority interest provision income taxis minority interest net taxis net earning continue operation discontinue operation earning net taxis gain disposal net taxis net earning earning common share basic net earning continue operation discontinue operation earning net taxis gain disposal net taxis net earning common share dilute net earning continue operation discontinue operation earning net taxis gain disposal net taxis net earning common share average common share outstanding basic dilute dividend declare common share accompany note integral financial statement annual report consolidate statement comprehensive income retain earning dollar millions year end december comprehensive income net earning comprehensive incomeloss foreign currency translation foreign currency translation reclassify net earning business divestiture foreign currency translation hedge net investment derivative qualify cash flow hedge net tax derivative qualify cash flow hedge reclassify net earning net tax minimum pension liability adjustment net tax pension postretirement benefit net tax pension postretirement benefit reclassify net earning net tax available sale security net tax available sale security reclassify net earning net tax total comprehensive lossincome comprehensive income retain earning retain earning january cumulative effect adoption fin net earning cash dividend declare retain earning december accompany note integral financial statement bristolmyers squibb consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable security receivables net allowance inventory net deferred income taxis net valuation allowance prepaid expense asset hold sale total current asset property plant equipment net goodwill intangible asset net deferred income taxis net valuation allowance asset total asset liability current liability shortterm borrowing account payable accrue expense defer income accrue rebate return foreign income taxis payable dividend payable accrue litigation liability liabilitie relate asset hold sale total current liability pension postretirement postemployment liability defer income foreign income taxis payable liability longterm debt total liability commitment contingency note stockholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue outstanding capital excess par value stock restrict stock accumulate comprehensive loss retain earning cost treasury stock million common share total stockholder equity total liability stockholder equity accompany note integral financial statement annual report consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity depreciation amortization defer income tax expensebenefit stockbase compensation expense acquire inprocess research development impairment charge gain sale product line business gainloss debt buybackrestructure interest rate swap termination loss sale property plant equipment gain sale imclone investment change operate asset liability receivable inventory defer income account payable foreign income taxis receivablepayable change operate asset liability net cash provide operating activity cash flow invest activity proceed sale marketable security purchase marketable security addition property plant equipment capitalize software proceed sale property plant equipment investment company proceed sale product line business proceed sale leaseback property milestone payment intangible asset purchase business net cash acquire proceed sale imclone share net cash provide byused investing activity cash flow financing activity shortterm repaymentsborrowing longterm debt borrowing longterm debt repayment interest rate swap termination issuance common stock stock plan excess tax benefit sharebase payment arrangement dividend pay net cash financing activity effect exchange rate cash cash equivalent increasedecrease cash cash equivalent cash cash equivalent begin period cash cash equivalent end period consolidate statement cash flow include activity discontinue operation accompany note integral financial statement bristolmyers squibb note accounting policy basis consolidation consolidate financial statement prepare conformity united states generally accept accounting principle include account bristolmyer squibb company control majorityowned subsidiary intercompany balance transaction eliminate company enter codevelopment cocommercialization license arrangement party therapeutic area term include upfront contingent payment arrangement party determine variable interest entity requirement fin r consolidation variable interest entity primarily company provide subordinate financial support result company consolidate financial result party reclassification certain prior year amount reclassify conform current year presentation change company reclassify certain receivables sale product alliance partner new presentation change previously report line item consolidated statement cash flow new presentation change net cash provide operating activity note receivables net use estimate preparation financial statement require use estimate assumption base complex judgment consider reasonable affect report amount asset liability disclosure contingent asset contingent liability date financial statement report amount revenue expense report period significant assumption employ estimate determine value intangible asset restructuring charge accrual sale rebate return accrual legal contingency tax asset tax liability stockbase compensation expense retirement postretirement benefit include actuarial assumption financial instrument observable market quote estimate apply revenue recognition policy actual result differ estimate result revenue recognition company recognize revenue title substantially risk reward ownership transfer customer generally revenue recognize time shipment case certain sale nutritional business certain nonus business pharmaceutical segment revenue recognize date receipt purchaser note alliance collaboration discussion revenue recognition relate alliance revenue reduce time recognition reflect expect return estimate base historical experience business trend additionally provision time revenue recognition discount rebate estimate sale allowance base historical experience update change fact circumstance appropriate provision record reduction revenue case new product product introduction extension exist line product company determine product similar therapeutic category company determine new product dissimilar characteristic exist product company reliably estimate expect return new product company defer recognition revenue right return long exist company develop sufficient historical experience estimate sale return annual report sale rebate return accrual sale rebate return accrual establish period relate revenue recognize result reduction sale establishment liability include accrue rebate return accrual record base estimate proportion record revenue result rebate return prime vendor chargeback accrual cash discount establish similar manner record reduction account receivable accrue liability reduction trade receivables follow december dollar millions medicaid rebate woman infant child rebates sale return manage health care rebate contract discount prime vendor chargeback cash discount adjustment income taxis provision income taxis determine asset liability approach accounting income taxis approach defer taxis represent future tax consequence expect occur report amount asset liability recover pay provision income taxis represent income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis company asset liability adjust change tax rate tax law change enact valuation allowance record reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment cash cash equivalent cash cash equivalent consist treasury back security bank deposit time deposit money market fund cash equivalent primarily highly liquid investment original maturity month time purchase record cost approximate fair value company maintain cash cash equivalent balance dollar foreign currency subject currency rate risk marketable security company determine appropriate classification marketable security available sale time purchase company investment marketable security report fair value december fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity decline fair value consider temporary charge earning consider temporary report component accumulate comprehensive income stockholder equity company use average cost method determine cost basis computing realize gain loss sale available sale security realize gain loss include expense net inventory valuation inventory generally state average cost excess market capital asset depreciation expenditure addition renewal improvement capitalize cost depreciation generally compute straightline method base estimate useful life relate asset estimate useful life major class depreciable asset year building year machinery equipment fixture company periodically evaluate current event circumstance indicate carry value depreciable asset recoverable bristolmyer squibb impairment longlive asset company periodically evaluate current fact circumstance indicate carry value depreciable asset hold recoverable circumstance determine exist estimate undiscounted future cash flow produce longlived asset appropriate grouping asset compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique include discount value estimate future cash flow company report asset dispose low carrying value estimate net realizable value capitalize software certain cost obtain internal use software significant system project capitalize amortize estimate useful life software range year cost obtain software project significant expense incur capitalize software net accumulate amortization include intangible asset net million million december respectively amortization expense million million million investment company account lessowne company ability exercise significant influence equity method accounting cost method company share net income loss equity investment include equity net income affiliate consolidated statement earning loss recognize expense net decline market value deem temporary company review equity investment impairment base determination decline market value investment company carry value temporary making determination company consider factor evaluate determine loss value recognize include company ability hold investment market price market price fluctuation investment publicly trade share inability investee sustain earning capacity justify carry investment acquisition company consolidate financial statement result operation reflect acquire business completion acquisition restate acquire business account purchase method accounting require asset acquire liability assume record date acquisition respective fair value excess purchase price estimate fair value net asset acquire record goodwill amount allocate acquire inprocess research development expense date acquisition goodwill recognize acquire net asset constitute business goodwill intangible asset goodwill test impairment annually twostep process step identify potential impairment second step measure impairment loss goodwill deem impaired carrying reporting unit goodwill exceed estimate fair value pharmaceutical segment include separate reporting unit base geography nutritional segment consist reporting unit company complete annual goodwill impairment assessment quarter monitor potential impairment remain quarter indicate impairment goodwill intangible asset net consist patentstrademark license technology capitalize software amortize straight line basis useful life range year intangible asset deem impair net carry value exceed estimate fair value restructure company recognize restructuring charge connection activity streamline operation rationalize manufacture facility result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place actual result vary estimate annual report product liability accrual product liability include associate legal cost record undiscounted basis probable liability incur liability reasonably estimate base exist information accrual adjust periodically assessment effort progress additional information available receivables relate insurance party recovery product liability record undiscounted basis probable recovery realize classified reduction litigation expense net consolidated statement earning contingency normal course business company subject loss contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability company record accrual loss contingency probable liability incur loss reasonably estimate company recognize gain contingency realize discussion contingency note legal proceeding contingency derivative financial instrument derivative financial instrument company principally management interest rate foreign currency exposure company hold issue derivative financial instrument speculative purpose company record derivative instrument balance sheet fair value change derivative fair value recognize earning specific hedge criterion meet derivative designate fair value hedge change fair value derivative hedge item attributable hedge risk recognize consolidated statement earning derivative designate cash flow hedge effective portion change fair value derivative record oci subsequently recognize consolidated statement earning hedge item affect earning cash flow classify consistent underlying hedged item purchase foreign currency option entire change fair value include measurement hedge effectiveness cash flow hedge ineffective portion change fair value cash flow hedge recognize charge credit earning company designates assign derivative hedge forecast transaction specific asset specific liability hedge asset liability sell extinguish forecast transaction hedge long expect occur company immediately recognize gain loss designate hedge financial instrument consolidate statement earning shipping handling cost company typically charge customer shipping handling cost ship handling cost include marketing sell administrative expense million million million advertising cost advertising cost expense incur advertising expense million million million research development research development cost expense incur company time time enter strategic alliance party company right develop manufacture market andor sell pharmaceutical product right own party result alliance company obligate payment alliance partner connection research development contingent achievement certain predetermine criterion milestone achieve prior regulatory approval product payment expense research development milestone payment connection regulatory approval include nonus regulatory approval additional indication capitalize amortize cost product sell remain useful life asset capitalize milestone payment test recoverability periodically event change circumstance indicate carrying amount recoverable company record research development net reimbursement connection collaboration agreement bristolmyers squibb acquire inprocess research development fair value inprocess research development acquire business combination determine base present value research project project cash flow income approach utilize consistent guidance practice aid issue american institute certify public accountant asset acquire business combination research development activity focus software electronic device pharmaceutical industry future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar product revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life research project underlie patent determine fair value research project expect revenue adjust technical risk completion result cash flow discount rate approximating company weightedaverage cost capital acquire inprocess research development expense incurred underlying product receive regulatory approval future alternative use addition cost nonrefundable relate acquisition licensing product receive regulatory approval market alternative future use charge earning incur earning share basic earning common share compute weightedaverage number share outstanding year dilute earning common share compute weightedaverage number share outstanding year plus incremental share outstanding assume exercise dilutive stock option restrict stock convertible instrument foreign currency translation statement earning company foreign subsidiary translate dollar average exchange rate net asset company foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation adjustment account include accumulate oci recently issue accounting standard effective january company adopt emerge issue task force eitf issue account nonrefundable advance payment good service receive use future research development activity nonrefundable advance payment good service render future research development activity defer capitalize amount recognize expense relate good deliver service perform good service long expect provide company adoption eitf material effect company consolidate financial statement effective january company adopt statement financial accounting sfas fair value option financial asset financial liability include amendment sfas account certain investment debt equity security permit entity measure certain financial asset financial liability fair value objective sfas improve financial reporting allow entity mitigate volatility report earning cause measurement relate asset liability different attribute apply complex hedge accounting provision sfas entity elect fair value option instrument report unrealize gain loss earning subsequent reporting date fair value option election irrevocable new election date occur sfas establishe presentation disclosure requirement help financial statement user understand effect entitys election earning eliminate disclosure requirement accounting standard asset liability measure fair value display face balance sheet company choose elect fair value option financial asset liability exist january elect fair value option financial asset liability asset liability previously carry fair value adoption sfas impact company consolidate financial statement effective january company adopt provision sfas fair value measurement financial asset liability asset liability carry fair value pronouncement define fair value establishe framework measure fair value expand disclosure fair value measurement implementation sfas nonfinancial asset liability effective january company adoption sfas relate financial asset liability material effect company consolidate financial statement adoption sfas respect non financial asset liability future expect material impact company consolidate financial statement annual report march fasb issue sfas disclosure derivative instrument hedging activity amendment sfas accounting derivative instrument hedge activity sfas require objective derivative instrument disclose term underlie risk accounting designation fair value derivative instrument gain loss need present tabular format order present complete picture effect derivative instrument sfas effective financial statement issue fiscal year begin november company provide require disclosure december consolidated financial statement december meeting fasb ratify consensus reach eitf issue accounting collaborative arrangement relate development commercialization intellectual property eitf conclude collaborative arrangement participant actively involve expose significant risk reward depend ultimate commercial success endeavor revenue cost incur party connection collaborative arrangement present gross net base criterion eitf report revenue gross principal versus net agent accounting literature payment collaborator evaluate present base nature arrangement term nature entitys business payment scope accounting literature nature purpose collaborative arrangement disclose accounting policy classification amount significant financial statement amount relate arrangement activity arrangement conduct separate legal entity account accounting literature require disclosure eitf apply entire collaborative agreement eitf effective fiscal year begin december apply retrospectively period present collaborative arrangement exist effective date accounting pronouncement material effect company consolidate financial statement december fasb issue sfas noncontrolle interest consolidate financial statementsan amendment arb sfas establish accounting reporting standard require ownership interest subsidiary hold party parent clearly identify label present consolidated balance sheet equity separate parent equity fasb require consolidate net income attributable parent noncontrolle interest clearly identify present face consolidate statement income change parent ownership interest parent retain control financial interest subsidiary account consistently subsidiary deconsolidate retain noncontrolle equity investment subsidiary initially measure fair value fasb require entity provide sufficient disclosure clearly identify distinguish interest parent interest noncontrolle owner fasb effective company january change company consolidate financial statement presentation december fasb issue sfas r business combination replace sfas business combination require recognition asset acquire liability assume noncontrolle interest acquiree acquisition date measure fair value date business combination achieve stage fasb require recognition identifiable asset liability noncontrolle interest acquiree amount fair value fasb require fair value acquire inprocess research development record indefinite live intangible contingent consideration record acquisition date restructuring acquisitionrelate deal cost expense incur addition excess fair value net asset acquire purchase price subsequent change estimate contingency record earning fasb apply company business combination acquisition date january july fasb issue fasb interpretation fin accounting uncertainty income taxis interpretation fasb statement case company effective january fin clarifie accounting uncertainty income taxis recognize enterprise financial statement accordance sfas accounting income taxis fin require tax position evaluate recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return difference tax position take tax return amount recognize financial statement record adjustment income taxis payable receivable adjustment defer taxis fin require expand disclosure end reporting period include tabular reconciliation unrecognized tax benefit company adopt fin january result adoption accounting pronouncement company recognize million previously unrecognized tax benefit account increase opening balance retain earning fasb issue fasb staff position fsp fin definition settlement fasb interpretation effective retroactively january fsp fin provide guidance determine tax position effectively settle purpose recognize previously unrecognized tax benefit adoption fsp fin effect company consolidate financial statement bristolmyer squibb note alliance collaboration sanofi company agreement sanofiaventis codevelopment cocommercialization avaproavalide angiotensin ii receptor antagonist indicate treatment hypertension diabetic nephropathy plavix platelet aggregation inhibitor worldwide alliance operate framework geographic territory america principally canada puerto rico latin american countries australia europe asia accordingly territory partnership form manage central expense market research development royalty supply finish product individual country general country level agreement copromote partnership form party sell brand comarket party operate sell brand independently place agreement expire later respect plavix respect avaproavalide americas australia europe asia ii expiration patent exclusivity right applicable territory company act operating partner territory cover americas australia own majority control interest territory sanofis ownership interest territory company consolidate country partnership result territory record sanofis share result minority interest net taxis million million million company record net sale territory comarkete country outside territory germany italy spain greece million million million cash flow operating activity partnership territory cover americas australia record operating activity company consolidate statement cash flow distribution partnership profit sanofi sanofis fund ongoing partnership operation occur routine basis record operating activity company consolidated statement cash flow sanofi act operating partner territory cover europe asia own majority financial control interest territory company ownership interest partnership territory company account investment partnership entity territory equity method record share result equity net income affiliate consolidated statement earning company share income partnership entity tax million million million company routinely receive distribution profit provide fund ongoing operation partnership territory cover europe asia transactions record operating activity company consolidate statement cash flow company sanofi alliance copromotion irbesartan company recognize income million million million relate amortization defer income associate sanofis million payment company acquisition interest irbesartan license formation alliance unrecognized portion defer income amount million million december respectively continue amortize expect expiration license follow summarize financial information company interest partnership sanofi territory cover europe asia year end december dollar million net sale gross profit net income current asset current liability otsuka company worldwide commercialization agreement otsuka pharmaceutical co ltd codevelop copromote otsuka abilify treatment schizophrenia bipolar mania disorder major depressive disorder japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt term agreement company purchase product otsuka perform finish manufacture sale company otsuka thirdparty customer product currently copromote otsuka united kingdom germany france spain germany spain product invoice thirdparty customer company behalf otsuka company record alliance revenue contractual share thirdparty net sale record expense relate product company recognize alliance revenue abilify ship risk reward ownership transfer thirdparty customer uk france annual report italy company presently exclusive distributor product company record net sale relate cost product sell expense company exclusive right sell abilify country europe americas number countries asia country company record net sale relate cost product sell agreement expire november entire european union eu agreement expire june country company exclusive right sell abilify agreement expire later th anniversary commercial sale country expiration applicable patent country company record net sale abilify million million million total milestone payment otsuka agreement december million million expense acquire inprocess research development remain million capitalize intangible asset net amortize cost product sell remain life agreement company amortize cost product sell million unamortized capitalize payment balance million million december respectively imclone company commercialization agreement expire september imclone codevelopment copromotion erbitux codevelopment copromotion right canada japan extent product commercialize countries erbitux indicate use treatment patient metastatic colorectal cancer use treatment squamous cell carcinoma head neck agreement cover north america imclone receive distribution fee base flat rate net sale north america october company imclone amend codevelopment agreement merck kgaa provide cocommercialization erbitux japan expire imclone ability terminate agreement determine commercially unreasonable imclone continue erbitux receive marketing approval japan july use erbitux treat patient advance recurrent colorectal cancer company record net sale erbitux million million million company amortize cost product sell million million million previously capitalize milestone payment account license acquisition unamortized portion approval payment record intangible asset net million million december respectively continue amortize remain term agreement initial execution commercialization agreement company acquire ownership interest imclone approximate time transaction note accounting investment equity method company record equity loss income affiliate adjust revenue recognize imclone preapprove milestone payment company prior million equity net income affiliate million million november eli lilly company acquire imclone result company sell share imclone billion recognize pretax gain million company continue marketing right erbitux believe right imclone investigational compound imcf gilead company gilead sciences inc joint venture develop commercialize atripla oncedaily single tablet threedrug regimen combine company sustiva gilead truvada emtricitabine tenofovir disoproxil fumarate canada europe atripla approve fda july health canada october european commission december commercialization country eu norway iceland gilead record atripla revenue canada countries europe consolidate result joint venture operating result company record revenue bulk efavirenz component atripla sale product joint venture thirdparty customer company net sale efavirenz component determine apply percentage atripla revenue approximate revenue sustiva brand limit number eu country company record revenue atripla company agree purchase product gilead distribute thirdparty customer company record revenue million million million relate atripla sale company account participation joint venture equity method accounting record share joint venture result equity net income affiliate consolidate statement earning company record equity loss joint venture gilead million million bristolmyer squibb astrazeneca january company enter worldwide japan codevelopment cocommercialization agreement astrazeneca plc codevelopment cocommercialization saxagliptin dppiv inhibitor saxagliptin agreement codevelopment cocommercialization dapagliflozin sodiumglucose contransporter sglt inhibitor sglt agreement compound study treatment diabete discover company term agreement company receive astrazeneca upfront payment million january october company receive astrazeneca milestone payment million june file new drug application food drug administration onglyza company propose onglyza approve fda european medicine evaluation agency serve trade saxagliptin upfront milestone payment defer recognize useful life product income company amortize income million upfront payment million unamortized portion upfront milestone payment million december million december additional milestone payment expect receive company successful achievement development regulatory event salesrelated milestone saxagliptin agreement company receive million development regulatory milestone meet additional million salesbased milestone meet sglt agreement company receive million development regulatory milestone meet additional million salesbased milestone meet agreement company astrazeneca share development commercialization cost majority development cost initial development plan pay astrazeneca additional development cost generally share equally company record development cost relate saxagliptin dapagliflozin net astrazenecas share research development expense agreement company jointly develop clinical marketing strategy share commercialization expense profitslosse equally global basis exclude japan company manufacture product pfizer april company pfizer inc enter worldwide codevelopment cocommercialization agreement apixaban anticoagulant discover company study prevention treatment broad range venous arterial thrombotic condition accordance term agreement pfizer upfront payment million company defer recognize life agreement income december company pfizer agree include japan worldwide agreement connection japan agreement pfizer additional upfront payment million december defer recognize useful life product income company amortize income million upfront payment million unamortized portion upfront payment million december million december pfizer fund development cost effective january go forward company fund company record apixaban development cost net pfizer share research development expense company receive additional payment million pfizer base development regulatory milestone company jointly develop clinical marketing strategy share commercialization expense profitslosse equally global basis manufacture product arrangement exelixis december company exelixis enter global codevelopment cocommercialization arrangement xl oral anticancer compound license xl utility ras raf mutant tumor development exelixis term arrangement company agree pay exelixis million execution agreement additional million company expense research development million execution agreement exelixis fund million development xl exelixis elect continue share development cost elect copromote exelixis fund future global development cost exclude japan share profitslosse equally fail election exelixis receive milestone royalty company fund development cost japan addition doubledigit royalty nonus sale company pay million development regulatory milestone meet additional million salesbased milestone meet addition company exelixis history collaboration identify develop promote oncology target december company exelixis enter oncology collaboration license agreement exelixis pursue development small molecule ind codevelopment copromotion term agreement company pay exelixis million upfront fee company pay exelixis million ind acceptance milestone exelixis elect fund development cost copromote party equally share development cost profit exelixis opt codevelopment copromotion agreement bms development commercial right successful pay exelixis development regulatory milestone million additional million salesbased milestone doubledigit royalty annual report note restructuring december july company announce productivity transformation initiative design fundamentally change way run business meet challenge change business environment advantage diverse opportunity marketplace company transform nextgeneration biopharma company create total billion annual productivity cost saving cost avoidance connection pti company aim achieve culture continuous improvement enhance efficiency effectiveness competitiveness substantially improve cost base charge associate previously announce pti estimate aggregate range billion billion include million cost incur incur cost net million gain relate sale mature product line business exact timing recognition pti charge predict certainty affect existence trigger event expense recognition factor include charge net termination benefit million million exit cost million million net restructuring charge include termination benefit workforce reduction approximately manufacturing sell administrative research development personnel geographic region follow table present detail expense incur segment corporateother connection restructuring activity termination termination exit termination exit dollar million benefit exit cost total benefit cost total benefit cost total pharmaceutical nutritional corporateother subtotal change estimate provision restructure net follow table represent reconciliation restructuring liability spend liability exit termination cost dollar million liability liability total liability january charge spend change estimate liability december charge spend change estimate liability december charge spend change estimate convatec divestiture liability december addition termination charge company recognize accelerate depreciation fix asset impairment charge shutdown cost million million million charge include cost product sell primarily relate rationalization company manufacture network pharmaceutical segment asset continue depreciate facility closure complete remain cost pti primarily attribute process standardization activity company recognize incur bristolmyer squibb note acquisition divestiture june company complete acquisition kosan biosciences inc cancer therapeutic company library novel compound include hsp inhibitor cancer microtubule stabilizer additional potential neurodegenerative disease net purchase price approximately million transaction account purchase method accounting purchase price preliminarily allocate acquiredinprocess research development million net asset million goodwill million october company complete acquisition adnexus therapeutics inc developer new therapeutic class biologic call adnectins net purchase price million addition event certain future development regulatory milestone achieve company obligate term agreement pay stockholder adnexus additional million transaction account purchase method accounting purchase price allocate acquiredinprocess research development million identifiable intangible asset million exist process technology future discovery net asset million goodwill million reflect additional defer tax asset million result operation acquisition include accompany consolidated financial statement date acquisition pro forma supplemental financial information include impact business combination material december company complete sale mature brand business locate egypt million cash glaxosmithkline result transaction company recognize pretax gain million million net tax fourth quarter august company complete divestiture convatec business january company complete divestiture bristolmyers squibb medical imaging note discontinued operation asset hold sale discussion divestiture july company complete sale bufferin excedrin brand japan asia exclude china taiwan certain oceanic country lion corporation japan million cash result transaction company recognize pretax gain million million net tax quarter january company complete sale inventory trademark patent intellectual property right relate dovonex treatment psoriasis warner chilcott company inc million cash addition company receive royalty base net sale dovonex end result transaction company recognize pretax gain million million net tax quarter note mead johnson nutrition company initial public offering february mead johnson nutrition company complete initial public offering ipo sell million share class common stock share net proceed receive approximately million allocate minority interest net taxis capital excess par value stock company stockholder equity accordance sfas noncontrolle interest consolidate financial statement amendment arb completion ipo company hold million share mead johnson class common stock million share mead johnson class b common stock right holder share class common stock class b common stock identical regard voting conversion share class common stock entitle vote share share class b common stock entitle vote share convertible time election holder share class common stock class b common stock automatically convert share class common stock certain circumstance completion ipo company hold interest mead johnson mead johnson continue consolidated financial reporting purpose company enter agreement relate separation mead johnson include separation agreement transitional service agreement tax matter agreement registration right agreement employee matter agreement february mead johnson enter year syndicate revolve credit facility agreement credit facility unsecured provide borrowing letter credit million annual report note discontinued operation asset hold sale august company complete divestiture convatec business cidron healthcare limited affiliate nordic capital fund vii avista capital partner lp avista gross purchase price approximately billion result pretax gain billion billion net tax include discontinue operation gross purchase price include estimate postclose purchase price adjustment base company estimate close work capital convatec business purchase price transaction gain subject future adjustment base actual closing work capital convatec business pursuant term stock asset purchase agreement date addition company record discontinued operation curtailment loss million special termination benefit million associate remeasurement japan pension plan obligation asset trigger decision sell convatec business result convatec business previously report separate operating segment include earning discontinue operation net taxis period present january company complete divestiture medical imaging avista gross purchase price approximately million exclude post closing adjustment result pretax gain million aftertax loss million include discontinue operation result medical imaging business previously include health care operating segment include earning discontinue operation net taxis period present net asset associate medical imaging business total approximately million reclassify asset liability hold sale december period time company continue generate cash flow report income statement activity expense net associate convatec medical imaging business activity rise cash flow income statement activity transitional nature generally result agreement intend facilitate orderly transfer business operation agreement include service accounting customer service distribution manufacturing activity convatec medical imaging business expect material company result operation cash flow convatec agreement extend period generally month majority range month transaction close date subject certain case limit extension medical imaging agreement extend period generally month majority range month transaction close date subject certain case close extension transitional service fee net identifiable direct cost recognize expense net amount million year end december follow summarize financial information relate convatec medical imaging business segregate continue operation report discontinue operation date disposition reflect cost certain service provide convatec medical imaging company cost allocate company convatec medical imaging service include limitation legal counsel insurance external audit fee payroll process certain human resource service information technology system support year end december convatec medical imaging dollar million net sale earning income tax curtailment loss special termination benefit provision income taxis earning net taxis gain disposal provision income taxis gainloss disposal net taxis bristolmyer squibb consolidate statement cash flow include convatec medical imaging business date disposition company use centralized approach cash management financing operation accordingly debt allocate business follow table include medical imaging asset liability segregate classified asset hold sale liability relate asset hold sale appropriate consolidated balance sheet december amount present adjusted exclude cash intercompany receivables payable business hold sale company exclude divestiture addition goodwill december million exclude follow summary net asset hold sale consider determine pretax gain sale quarter asset generate operating result cash flow include consolidated balance sheet asset hold sale december dollar million december medical imaging asset receivables net allowance inventory net asset property plant equipment net intangible asset net total asset hold sale liability account payable accrue liability total liability relate asset hold sale net asset hold sale annual report note earning share numerator basic earning share net earning available common stockholder numerator diluted earning share net earning available common stockholder interest expense add assume conversion convertible debt common stock denominator basic earning share weightedaverage number common stock outstanding period denominator diluted earning share weightedaverage share outstanding adjusted effect dilutive stock option restrict share assume conversion convertible debt common stock computation basic diluted earning common share follow year end december dollar million share datum basic net earning continue operation discontinue operation earning net taxis gain disposal net taxis net earning basic earning share average common share outstanding basic net earning continue operation discontinue operation earning net taxis gain disposal net taxis net earning common share dilute net earning continue operation interest expense conversion convertible debt net taxis net earning continue operation diluted earning common share calculation discontinue operation earning net taxis gain disposal net taxis net earning dilute earning share average common share outstanding basic conversion convertible debt incremental share outstanding assume exerciseveste dilutive stock optionsrestricte stock average common share outstanding diluted net earning continue operation discontinue operation earning net taxis gain disposal net taxis net earning common share weightedaverage share issuable exercise stock option million million million include diluted earning share calculation antidilutive addition million share assume conversion convertible debt include diluted earning share calculation antidilutive bristolmyer squibb note expense net component expense net follow year end december dollar million interest expense interest income ar impairment charge gainloss debt buyback termination interest rate swap agreement foreign exchange transaction gainslosse net expense net interest expense include million net interest rate swap gain net interest rate swap loss million million note financial instrument additional discussion terminate swap contract interest income relate primarily interest earn cash cash equivalent investment marketable security detail auction rate security impairment note cash cash equivalent marketable security net include income thirdparty contract manufacture certain royalty income expense gain loss sale property plant equipment gain loss sale marketable security include million loss sale ar insurance recovery certain litigation chargesrecoverie convatec medical imaging net transitional service fee amortization certain upfront payment relate company alliance note alliance collaboration note income taxis component earningsloss continue operation income taxis minority interest follow year end december dollar million nonus amount categorize base location tax authority provisionbenefit income taxis attributable continue operation consist year end december dollar millions current nonus defer nonus annual report effective tax rate company provision income taxis different compute apply statutory federal income tax rate earning continue operation income taxis minority interest result follow earning income taxis minority interest dollar million earning continue operation income taxis minority interest statutory rate foreign tax effect operation ireland puerto rico switzerland state local taxis net valuation allowance federal foreign contingent tax matter acquire inprocess research development expense federal research development tax credit federal foreign valuation allowance impairment financial instrument foreign increase effective tax rate primarily high pretax income include gain sale imclone earning mix high tax jurisdiction partially offset factor low nondeductible charge acquire inprocess research development expense low ar impairment charge little tax benefit tax rate favorably impact benefit million tax relate final settlement audit internal revenue service tax rate unfavorably impact impairment company investment certain ar little tax benefit nondeductible writeoff acquire inprocess research development expense relate acquisition adnexus partially offset tax benefit million quarter favorable resolution certain tax matter internal revenue service relate deductibility litigation settlement expense foreign tax credit claim effective tax rate unfavorably impact elimination tax benefit section internal revenue code treatment provision portion certain litigation reserve nondeductible partially offset favorable tax legislation enact related tax treatment certain intercompany transaction company foreign subsidiary implementation tax planning strategy relate utilization certain charitable contribution bristolmyers squibb defer taxis valuation allowance component current noncurrent defer income tax assetsliabilitie follow december dollar millions acquire inprocess research development intercompany profit inventory item federal foreign tax credit carryforward defer income federal research development tax credit carryforward federal charitable contribution carryforward state net operating loss carryforward foreign net operating loss carryforward foreign defer tax asset pension postretirement benefit depreciation sharebase compensation repatriation foreign earning legal settlement tax deductible goodwill milestone payment license fee net valuation allowance defer tax asset net recognize deferred income taxis current deferred income taxis noncurrent foreign income taxis payable liability noncurrent total company establish valuation allowance defer tax asset company determine likely defer tax asset realize december valuation allowance million establish follow item million state defer tax asset million foreign net operating loss tax credit carryforward million state net operating loss tax credit carryforward million relate impair financial instrument million federal state defer tax asset relate adnexus kosan acquisition offset goodwill company recognize significant defer tax asset december relate federal foreign tax credit carryforward million federal research development tax credit carryforward million federal charitable contribution carryforward fully utilize gain relate convatec medical imaging divestiture foreign tax credit research development tax credit carryforward expire vary amount begin foreign tax credit research development tax credit carryforward reduce derecognition fin convatec medical imaging divestiture result significant reduction foreign tax credit research development tax credit carryforward realization foreign tax credit research development tax credit carryforward dependent generating sufficient domesticsource taxable income prior expiration realization assure management believe likely defer tax asset realize income taxis pay year million million million discuss tax rate favorably impact benefit million tax relate final settlement audit internal revenue service final settlement relate joint committee congress approval foreign tax credit carryback claim company receive million cash refund include interest current tax benefit realize exercise stock option credit capital excess par value stock million million annual report december company approximately billion undistributed earning foreign subsidiary taxis provide company invest expect invest undistributed earning permanently offshore future earning repatriate company determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide company conduct business country world subject tax numerous jurisdiction result business activity company file significant number tax return subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report company require year resolve company establish liability possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation company adopt provision fin january result recognition million previously unrecognized tax benefit account increase opening balance retain earning fin require expand disclosure end annual reporting period include tabular reconciliation unrecognized tax benefit certain information interest penalty amount reflect company uncertain tax position tabular reconciliation company change uncertain tax position january december january december follow unrecognized unrecognized income tax unrecognized income tax benefit include interest federal state benefit defer penalty net foreign include interest income tax defer income tax dollar million tax benefit interest penalty penalty benefit benefit total uncertain tax position recognize impact effective tax rate january add tax attributable defer tax item january balance gross uncertain tax position january gross addition tax position relate current year gross reduction tax position relate current year gross addition tax position relate prior year gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance gross uncertain tax position december tax attributable defer tax item december total uncertain tax position recognize impact effective tax rate december total uncertain tax position recognize impact effective tax rate january add tax attributable defer tax item january balance gross uncertain tax position january gross addition tax position relate current year gross reduction tax position relate current year gross addition tax position relate prior year gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance gross uncertain tax position december tax attributable defer tax item december total uncertain tax position recognize impact effective tax rate december annual tabular reconciliation require fin require gross presentation unrecognize tax benefit gross basis reduction defer tax asset company total unrecognized tax benefit january exclude interest penalty million uncertain tax benefit december record company defer tax asset extent uncertainty directly relate asset record current noncurrent income taxis payable bristolmyer squibb total gross uncertain tax benefit december exclude interest penalty decrease million reduction primarily favorable resolution uncertain tax position partially offset additional uncertain tax benefit accrue include gross reduction tax position relate prior year million uncertain tax position long include fin table result disposition business include balance unrecognized tax benefit million uncertain tax position january million december ultimate deductibility highly certain uncertainty time deductibility impact defer tax accounting interest penaltie applicable disallowance short deductibility period affect annual effective tax rate accelerate payment cash tax authority utilization tax attribute early period amount unrecognized tax benefit recognize impact effective tax rate million january million december company classify interest penalty relate unrecognized tax benefit income tax expense amount reflect separately reconciliation total interest penalty relate uncertain tax position recognize consolidated statement earning net benefit million interest million penalty net benefit interest result million additional accrual million reduction interest net benefit penalty result million additional accrual million reduction penalty total interest penalty relate uncertain tax position recognize consolidated balance sheet december million interest million penalty company currently examination number tax authority include major tax jurisdiction list table propose adjustment tax issue transfer price certain tax credit deductibility certain expense company estimate reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits settlement involve payment additional taxis adjustment certain defer taxis andor recognition tax benefit company anticipate reasonably possible new issue raise tax authority require increase balance unrecognized tax benefit estimate increase reasonably company believe adequately provide open tax year tax jurisdiction fin company file income tax return federal jurisdiction state foreign jurisdiction exception company subject federal state local nonus income tax examination tax authority follow summary major tax jurisdiction tax authority assert additional taxis company base tax year currently audit subsequent year likely audit canada france germany italy mexico annual report note fair value measurement state note accounting policy january company adopt method fair value describe sfas value financial asset liability define sfas fair value base price receive sell asset pay transfer liability orderly transaction market participant measurement date order increase consistency comparability fair value measurement sfas establish fair value hierarchy prioritize observable unobservable input measure fair value broad level describe level quote price unadjuste active market accessible measurement date identical asset liability fair value hierarchy give high priority level input level observable price base input quote active market corroborate market datum level unobservable input little market datum available fair value hierarchy give low priority level input determine fair value company utilize valuation technique maximize use observable input minimize use unobservable input extent possible consider counterparty credit risk assessment fair value company choose elect fair value option prescribe sfas financial asset liability previously carry fair value material financial asset liability carry fair value short long term debt obligation trade account receivable payable report carry value financial asset liability carry fair value december classify table category describe dollar million level level level total available sale treasury bills equity security treasurybacke security float rate security auction rate security total available sale asset derivative interest rate swap derivative foreign exchange derivative total derivative asset total asset fair value dollar million level level level total derivative foreign exchange derivative natural gas contract total derivative liability total liability fair value company asset utilize level input fair value measurement consist auction rate security float rate security lack observable market quote company ars investment portfolio company utilize valuation model rely exclusively level input include base expect cash flow stream collateral value include assessment counterparty credit quality default risk underlie security discount rate overall capital market liquidity valuation company ars investment portfolio subject uncertainty difficult predict factor impact company valuation include change credit rating security underlie asset support security rate default underlie asset underlie collateral value discount rate counterparty risk ongoing strength quality market credit liquidity company determination fair value ar investment portfolio december include indicative price receive external bank internally develop valuation base indicative bid receive underlying asset security nonobservable evidence fair value ar continue pay interest accord state term continued severity capital market length time ar mature company believe recovery long probable discussion company december fair value carry value rollforward ar activity include sale otherthantemporary impairment charge record note cash cash equivalent marketable security bristolmyers squibb company frs primarily rate abaa well frs longterm debt security coupon reset periodically benchmark interest rate underlie asset frs consist primarily consumer loan auto loan collateralize loan obligation monoline security assetbacke security corporate bond loan general frs market liquid active continue credit liquidity concern result availability observable market quote active market level input market quote similar identical asset liability input derive principally corroborate observable market datum correlation mean level input company markstomarket frs base indicative pricing indicative price quote represent individual broker assessment base similar asset valuation technique analyze underlying asset frs current lack active market company frs general lack transparency underlie asset company rely qualitative analysis include discussion broker fund manager default risk underlie security overall capital market liquidity level input value frs portfolio discussion company december fair value carry value rollforward activity occur note cash cash equivalent marketable security financial asset liability utilize level level input company utilize direct indirect observable price quote include libor euribor yield curves foreign exchange forward price nymex future price common stock price quote summary valuation technique level level financial asset liabilitie treasury bill treasurybacke security value quote market price broker dealer quotation transparent pricing source report date equity security value quote stock price new york stock exchange national association security dealer automate quotation system report date interest rate swap derivative asset liability value libor euribor yield curve credit valuation adjustment report date counterpartie contract financial institution experience downgrade valuation fluctuate considerably periodtoperiod volatility underlie interest rate drive market condition duration swap addition credit valuation adjustment significant impact valuation company interest rate swap change counterparty credit rating credit default swap spread foreign exchange derivative asset liability value quote forward foreign exchange price report date counterpartie contract financial institution experience downgrade valuation fluctuate considerably periodtoperiod volatility underlie foreign currency shortterm maturity company foreign exchange derivative generally month counterparty credit risk significant natural gas forward contract value nymex future price natural gas reporting date counterpartie contract financial institution experience downgrade valuation fluctuate considerably periodtoperiod volatility underlie natural gas price shortterm maturity companys natural gas derivative month counterparty credit risk significant increase decrease aggregate fair value financial asset liability measure fair value significant impact company liquidity financial flexibility approximately fair value net financial asset treasury bill treasurybacke security company elect fair value option financial asset liability exist january transact future transact financial asset liability evaluate fair value election prescribe sfas fair value provision sfas company elect fair value option billion senior note issue annual report note cash cash equivalent marketable security cash cash equivalent december million primarily consist treasurybacke security cash cash equivalent december million primarily consist bank deposit time deposit money market fund cash equivalent primarily highly liquid investment original maturity month time purchase record cost approximate fair value company maintain cash cash equivalent balance dollar foreign currency subject currency rate risk marketable security december primarily consist treasury bill dollardenominate frs company frs holding downgrade december rating primarily aaaaaa rating range aaaaaa abaa december frs longterm debt security coupon reset periodically benchmark interest rate underlie asset company frs consist primarily consumer loan auto loan collateralize loan obligation monoline security assetbacke security corporate bond loan company account marketable security accordance sfas account certain investment debt equity security classifie available sale noncurrent frs classified noncurrent asset december follow table summarize company current noncurrent marketable security december include dollardenominated frs ar account available sale debt security december unrealize lossgain accumulate dollar million cost fair value carry value oci current available sale float rate security treasury bill total current noncurrent available sale auction rate security float rate security total noncurrent december unrealize lossgain accumulate dollar million cost fair value carry value oci current available sale float rate security total current noncurrent available sale auction rate security total noncurrent company recognize pretax otherthantemporary impairment charge million respectively million loss sale certain security december company principal value frs amount million company receive million principal par primarily frs mature march temporarily reduce fair value remain frs million million unrealized loss accumulate oci addition company reclassify million remain frs maturity date current asset noncurrent asset liquidity concern continue uncertainty capital market bristolmyers squibb company receive million connection sale ar carry value million result loss million addition million otherthantemporary impairment charge recognize include million previously determine temporary december impairment charge require analysis otherthan temporary impairment factor include severity duration decline value future prospect issuer company ability intent hold security recovery ar sell security generally back subprime mortgage collateralize debt obligation structure credit ar remain december primarily represent interest insurance securitization less extent structure credit follow table summarize activity financial asset fair value measurement estimate utilize level input ar frs noncurrent dollar million current frs frs ar total carrying value january settlement transfer current noncurrent total loss include earning include comprehensive income carrying value december discussion fair value financial instrument include ar frs note fair value measurement contractual maturity carry value available sale debt security december follow dollar million year year year year total available sale float rate security auction rate security treasury bill total available sale note receivables net major category receivables follow december dollar million trade receivables alliance partner receivables income tax refund claim miscellaneous receivable allowance receivables net receivable net deferred income sale product alliance partner recognition revenue result correspond reclassification reduced alliance partner receivables defer income million million december respectively additional information company alliance partner note alliance collaboration aggregate receivable pharmaceutical wholesaler represent total trade receivables december respectively annual report note inventory net major category inventory follow december dollar million finish good work process raw packaging material inventory net inventory expect remain onhand year million million december respectively include noncurrent asset note property plant equipment net major category property plant equipment follow december dollar million land building machinery equipment fixture construction progress accumulate depreciation property plant equipment net capitalize interest million million million note goodwill change carry goodwill segment year end december follow convatec pharmaceutical nutritional medical dollar million segment segment image total balance january acquisition adnexus adjustment balance january sale medical imaging sale convatec sale mature brand business egypt acquisition kosan adnexus purchase price adjustment balance december note acquisition divestiture detail bristolmyers squibb note intangible asset net december intangible asset consist follow total intangible patentstrademark license technology capitalize software asset dollar millions gross carrying accumulate amortization intangible asset net change carry intangible asset year end december follow total intangible asset dollar million intangible asset net carrying january addition acquisition adnexus amortization medical imaging asset hold sale sale convatec impairment charge intangible asset net carrying december impairment charge relate certain patent product right acquire dupont result development program abandon license termination amortization expense intangible asset million million million amortization expense intangible asset relate convatec medical imaging reflect discontinue operation million million million expect amortization expense relate current net carrying intangible asset follow year end december dollar million later year note accrue expense major category accrue expense follow december dollar million employee compensation benefit royaltie accrue research development restructure current pension postretirement benefit annual report note shortterm borrowing longterm debt shortterm borrowing million million december respectively september company repay million principal million aggregate principal float rate convertible senior debenture result partial redemption note holder portion remain balance million redeem holder par september fundamental change ownership company occur remain debt callable par time issuer debenture conversion price conversion rate share subject certain antidilutive adjustment maximum conversion rate share debenture pay interest quarterly annual rate equal month libor reset quarterly minus yield zero august february company repay million note million yen note respectively december company obtain billion year revolve credit facility syndicate lender extendable anniversary date consent lender facility contain customary term condition include financial covenant ratio consolidated debt consolidated capital exceed end quarter company compliance covenant inception new facility borrowing outstanding revolve credit facility december component longterm debt follow december december dollar million principal value note note euro note euro note note note debenture debenture debenture float rate convertible senior debenture industrial revenue bond yen note variable rate industrial revenue bond subtotal adjustment principal value fair value interest rate swap unamortize proceed swap termination unamortized bond discount discussion company interest rate swap refer note financial instrument bristolmyers squibb november december company repurchase approximately million principal debt terminate million notional interest rate swap result gain million report expense net table summarize debt repurchase relate activity principal repurchase swap termination earning dollar million price gain repurchase proceed impact note debenture debenture note total company issue million aggregate principal note billion aggregate principal note collectively issue note register public offer interest payment november year beginning november issue note senior unsecured obligation company rank equally right payment company exist future senior unsecured indebtedness company redeem issue note time redemption price equal great par value calculate base sum present value remain schedule payment set forth prospectus supplement date april december company terminate million notional fixedtofloate interest rate swap agreement relate note receive proceed million proceed recognize interest expense remain life underlie debt september company terminate million notional fixedtofloate interest rate swap agreement relate million debenture receive proceed million proceed recognize interest expense remain life underlie debt approximately million pretax recognize year discussion company swap termination refer note financial instrument include payment interest rate swap cash payment interest million million million cash receipt interest rate swap million million million exclude cash payment interest company principal value longterm debt obligation million december million million remain million later december company provide total million financial guarantee form standby letter credit performance bond standby letter credit insurance company support thirdparty liability program performance bond issue support range ongoing operating activity include sale company product hospital foreign ministry health bond custom duty value add tax guarantee relate miscellaneous legal action significant majority company outstanding financial guarantee expire year expect fund note stockholder equity change common share treasury stock capital excess par value stock restrict stock follow cost capital excess common share treasury treasury par value restrict dollar share million issue stock stock stock stock balance january employee stock compensation plan balance december employee stock compensation plan balance december employee stock compensation plan balance december share company prefer stock convertible share common stock callable company option reduction number issue share prefer stock conversion share common stock annual report accumulate balance relate component oci net taxis follow pension accumulate foreign derivative minimum currency qualify cash pension postretirement available comprehensive dollar million translation flow hedge liability benefit sale security incomeloss balance january comprehensive incomeloss adjustment adoption sfas balance december comprehensive incomeloss balance december comprehensive incomeloss balance december note employee stock benefit plan employee stock plan stockholder approve company stock award incentive plan plan plan replace stock incentive plan plan expire plan provide million new share common stock reserve delivery participant plus share remain available new grant plan share recapture outstanding award plan number share actually deliver participant connection award restriction lapse count number share reserve share tender prior year pay purchase price option number share previously utilize satisfy withholding tax obligation exercise continue available reserve december million million share common stock respectively reserve issuance pursuant stock plan option conversion prefer stock million million share available grant active plan december respectively adjust combination plan company plan plan executive officer key employee grant option purchase company common stock market price date option grant option generally exercisable installment year fourth anniversary grant date maximum term year generally company issue share stock option exercise treasury stock additionally plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price december thousand stock appreciation right outstanding treat liability award plan plan provide grant common stock key employee subject restriction continuous employment restriction generally expire year period date grant compensation expense recognize restrict period quarter company begin grant restrict stock unit instead restrict stock stock unit right receive stock end specify vest period stock unit voting right plan plan incorporate company longterm performance awards award deliver form target number performance share year cycle award annual goal set beginning performance period base earning share sale maximum performance result maximum payout award award addition onetime special performance award grant performance period special performance award annual goal set beginning performance period base pretax operate margin operate cash flow maximum performance result maximum payout goal award set year period base cumulative earning share cumulative sale ultimate payout modify company total stockholder return versus company proxy peer group maximum performance measure result maximum payout target threshold target meet performance period payment plan teamshare stock option plan terminate january fulltime employee exclude key executive grant option purchase company common stock market price date option grant company authorize million share issuance plan individual grant generally exercisable evenly fourth fifth anniversary grant date maximum term year option million share exercise plan december bristolmyers squibb company result operation year end december reflect impact sfas r sharedbase payment include impact expense stock option company elect alternative method provide fsp r transition election relate accounting tax effect sharebase payment award determine company pool excess tax benefit follow table summarize stockbased compensation expense relate employee stock option restrict stock longterm performance award year end december year end december dollar million stock option restrict stock longterm performance share total stockbase compensation expense stockbase compensation expense recognize consolidated statement earning follow year end december dollar million cost product sell marketing sell administrative research development total stockbase compensation expense defer tax benefit stockbase compensation expense net taxis stockbase compensation expense million million million include discontinue operation stock option summary stock option activity follow share common stock weightedaverage share million issue plan exercise price share balance january grant exercise expire forfeit balance december grant exercise expire forfeit balance december grant exercise expire forfeit balance december information relate stock option grant exercise plan plan summarize follow year end december amount million share datum stock option grant weightedaverage grantdate fair value share total intrinsic value stock option exercise cash proceed exercise stock option december million total unrecognized compensation cost relate stock option expect recognize weightedaverage period year annual report follow table summarize information concern company stock compensation plan currently outstanding exercisable option number security issue weightedaverage exercise exercise outstanding option price outstanding share million right option right plan category equity compensation plan approve security holder equity compensation plan approve security holder share plan long issue follow table summarize significant range outstanding exercisable option december amount million share datum option outstanding option exercisable weighted average weighted weight remain average aggregate average weight aggregate contractual exercise intrinsic remain average intrinsic number life price value number contractual life exercise price value range exercise price outstanding year share million exercisable year share million vest expect vest aggregate intrinsic value precede table represent total pretax intrinsic value base company close stock price december receive option holder option holder exercise option date total number inthemoney option exercisable december million december million outstanding option exercisable weightedaverage exercise price fair value employee stock option grant estimate date grant blackschole option pricing model stock option service condition monte carlo simulation model option service market condition follow table present weightedaverage assumption valuation year end december expect volatility riskfree interest rate dividend yield expect life yrs yrs yrs company derive expect volatility assumption require blackschole model calculate year historical volatility weighting equally derive imply volatility selection blend historical imply volatility approach base company assessment calculation expect volatility representative future stock price trend historical volatility riskfree interest rate assumption base treasury yield curve effect time grant dividend yield assumption base company history expectation dividend payout expect life employee stock option represent weightedaverage period stock option expect remain outstanding derive output latticebinomial model expect life employee stock option impact underlying assumption calibration company model latticebinomial model assume employee exercise behavior function option remain vested life extent option inthemoney latticebinomial model estimate bristolmyer squibb probability exercise function variable base entire history exercise cancellation past option grant company stockbase compensation expense base award ultimately expect vest forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate company acquire adnexus october acquisition agreement company assume million share adnexu incentive stock option isos replace million share company isos convert option retain original vest schedule include vest commencement date expiration date blackschole model determine expect term individual isos valuation result weightedaverage expect term year weightedaverage fair value october restrict stock award restrict stock unit fair value nonveste share company common stock determine base average trading price company common stock grant date restrict share activity follow weightedaverage share thousand number share grantdate fair value nonveste share january grant vested forfeited nonveste share december grant vested forfeited nonveste share december grant vested forfeited nonveste share december expect vest december million total unrecognized compensation cost relate nonveste restrict stock cost expect recognize weightedaverage period year total fair value nonveste share share unit grant recognize compensation expense million million million total fair value share share unit vest million longterm performance award adoption sfas r fair value performance award estimate date grant monte carlo simulation model market condition monte carlo simulation model utilize multiple input variable determine probability satisfy market condition stipulate award grant calculate fair market value longterm performance award performance award these award contain market condition fair value base closing trading price company common stock grant date valuation model award follow assumption weightedaverage expect riskfree grant year grant date expect volatility dividend yield interest rate weightedaverage expect volatility base year historical volatility level company common stock expect dividend yield base historical dividend payment riskfree interest rate reflect yield year zero coupon treasury bond base performance share contractual term fair value performance award amortize performance period award annual report information relate performance award plan plan summarize follow share thousand performance share outstanding performance cycle weightedaverage grant date measurement date share grant grantdate fair value december december annually annually annually annually annually annually total outstanding unrecognized compensation cost relate performance share plan million december expect recognize weightedaverage period year accuracy fair value estimate company determination fair value stockbase payment award date grant optionprice model affect company stock price assumption number highly complex subjective variable variable include limited company expect stock price volatility term award actual project employee stock option exercise behavior optionprice model develop use estimate value trade option vest hedge restriction fully transferable company employee stock option certain characteristic significantly different trade option change subjective assumption materially affect estimate value management opinion exist valuation model provide accurate measure fair value company employee stock option fair value employee stock option determine accordance sfas r staff accounting bulletin sab sharebase payment optionprice model value indicative fair value observe willing buyerwilling seller market transaction note financial instrument company expose market risk change currency exchange rate interest rate less extent natural gas pricing reduce risk company enter certain derivative financial instrument available costeffective basis hedge underlie economic exposure company primary net foreign currency translation exposure euro japanese yen canadian dollar chinese renminbi mexican peso manage exposure company utilize foreign currency contract subject cash flow hedge accounting treatment instrument manage consolidated basis efficiently net exposure advantage natural offset company use derivative instrument interest rate risk management strategy derivative instrument comprise principally fixedtofloate rate interest rate swap subject fairvalue hedge accounting treatment derivative financial instrument speculative purpose cash flow hedge foreign exchange contract company utilize foreign currency contract hedge anticipate transaction primarily intercompany transaction certain foreign currency designate derivative instrument foreign currency cash flow hedge appropriate notional amount company foreign exchange derivative contract december million million respectively derivative majority qualify hedge future anticipate cash flow effective portion change fair value temporarily defer accumulate oci recognize earning hedge item affect earning bristolmyer squibb table summarize company outstanding foreign exchange forward contract december fair value foreign exchange forward contract base yearend currency rate fair value foreign exchange forward contract view relation fair value underlie hedged transaction overall reduction exposure adverse fluctuation foreign currency exchange rate weightedaverage fair value dollar million currency rate strike price notional assetliability maturity foreign exchange forwards cash flow hedge australian dollar brazilian real british pound canadian dollar euro japanese yen japanese yen mexican peso polish zloty swedish krona swiss franc total cash flow hedge december total notional fair market value contract buy japanese yen million million respectively fully offset total notional fair market value sell contract million million respectively december company hold foreign exchange option contract buy sell japanese yen december balance defer gain foreign exchange forward contract qualified cash flow hedge accounting include accumulate oci pretax basis million million net tax expect reclassify earning month sfas accounting derivative instrument hedging activity require company perform periodic assessment hedge effectiveness company assess effectiveness inception hedge quarterly basis assessment determine derivative designate qualifying hedge continue highly effective offset change cash flow hedge item ineffective portion fair value long defer accumulate oci include current period earning year end december impact hedge ineffectiveness earning significant additionally year end december impact discontinue hedge pretax gain million pretax loss million million respectively natural gas contract company utilize forward contract hedge anticipate purchase natural gas designate derivative instrument cash flow hedge appropriate derivative majority qualify hedge future anticipate cash flow effective portion change fair value temporarily defer accumulate oci recognize earning hedge item affect earning year end december impact discontinue natural gas hedge pretax loss million material year end december nonqualifye foreign exchange contract addition foreign exchange contract note company utilize forward contract hedge foreign currencydenominate monetary asset liability primary objective forward contract protect dollar value foreign currency denominate monetary asset liability effect volatility foreign exchange rate occur prior receipt settlement dollar forward contract designate hedge marktomarket expense net notional fair value amount purchase sell foreign exchange forward contract december material furthermore company use foreign exchange forward contract offset exposure certain asset liability earning denominate certain foreign currency foreign exchange forward contract designate hedge change fair value derivative recognize earning expense net occur notional fair value amount foreign exchange forward contract december material annual report hedge net investment company use nonus dollar borrowing primarily million note million note hedge foreign currency exposure company net investment certain foreign affiliate nonus dollar borrowing designate hedge net investment effective portion foreign exchange gain loss hedge record foreign currency translation component accumulate oci company unhedged exposure net foreign currencydenominate asset liability approximately million million december respectively primarily japan china mexico australia uk thailand fair value hedge interest rate contract company use derivative instrument interest rate risk management strategy derivative instrument comprise principally fixedtofloate rate interest rate swap subject fairvalue hedge accounting treatment november connection funding retirement fix rate debt company execute fixedto float interest rate swap convert billion billion billion inception company newlyissue fix rate debt pay variable rate debt company execute additional fixedtofloate interest rate swap convert billion company newlyissue fix rate debt pay variable rate total notional amount outstanding interest rate swap billion billion billion december billion billion billion december billion billion billion december company recognize net decrease interest expense million net increase million million respectively swap underlie debt hedge record fair value swap generally hold maturity intend create appropriate balance fix float rate debt company swap qualify fair value hedge terminate prior maturity date report carry value underlie debt amortize earning remain life debt swap qualify cash flow hedge terminate report accumulate oci amortize earning remain life debt december balance defer loss forward start swap include accumulate oci million reclassify earning remain life debt november december company repurchase approximately million principal debt terminate million notional interest rate swap result gain million report expense net company terminate million notional fixedtofloate interest rate swap agreement total proceed million proceed swap termination recognize interest expense remain life underlie debt discussion company debt buyback refer note shortterm borrowing longterm debt follow table summarize interest rate swap outstanding december earning impact terminate interest rate swap interest rate swap outstanding notio nal year fair interest rate swap underlie debt variable rate receive transaction maturity value dollar million swap associate note month libor note month libor million note month eur euribor million note month eur euribor note month libor note month libor note month libor note month libor bristolmyers squibb earning impact terminate interest rate swap unrecognized gainslosse pretax incomeexpense recognize year longterm interest rate swap termination debt comprehensive loss dollar million interest rate swap lock associate note note swap associate note note note note note note note note follow table summarize company fair value outstanding derivative december dollar million balance sheet location balance sheet location derivative designate hedge instrument interest rate contract asset accrue expense foreign exchange contract asset accrue expense hedge net investment shortterm borrowing hedge net investment longterm debt natural gas contract accrue expense derivative designate hedge instrument foreign exchange contract asset accrue expense total derivative impact earning interest rate swap qualify fair value hedge year end december follow dollar million interest incomeexpense terminate gain recognize expense net total impact oci earning foreign exchange natural gas forward qualified cash flow hedge follow foreign exchange natural gas forward start contract contract swap total impact dollar million gainloss recognize oci december effective portion loss reclassify oci cost product sell effective portion gainloss recognize expense net discontinue ineffective portion annual report impact oci earning nonderivative debt designate hedge net investment year end december follow net investment hedge dollar million loss recognize oci effective portion gain recognize expense net ineffective portion exclude effectiveness testing impact earning nonqualifye derivative year end december follow dollar million gain recognize expense net discussion fair value financial instrument note fair value measurement discussion cash cash equivalent marketable security note cash cash equivalent marketable security longterm debt difference fair value carry value material january company terminate fixedtofloate interest rate swap notional million result million gain amortize remain life debt note segment information segment information consistent management review business make invest resource allocation decision assess operating performance company report financial operating information segmentspharmaceutical nutritional pharmaceutical segment comprise global pharmaceutical international consumer medicine business nutritional segment consist mead johnson primarily infant formula business children nutritional business january august company complete divestiture medical imaging convatec business respectively result medical imaging convatec business previously include health care convatec operating segment respectively include discontinue operation additional information divestiture medical imaging convatec note acquisition divestiture note discontinue operation asset hold sale company product sell principally wholesale retail trade nationally internationally certain product sell drug manufacturer hospital clinic government agency medical profession gross sale pharmaceutical wholesaler account approximately company total gross sale company total gross sale company total gross sale earning continue operation net sale income taxis minority interest yearend asset dollar million pharmaceutical nutritional total segment corporateother total bristolmyer squibb corporateother asset include cash cash equivalent marketable security asset discontinue operation certain asset earning continue operation income taxis minority interest report corporateother consist dollar million corporate administrative expense stockbase compensation expense provision restructure net litigation expense net interest expense interest income ar impairment charge gain sale imclone share gain sale product line business gainloss debt buyback termination interest rate swap agreement total corporateother earning continue operation income taxis minority interest net sale company key product follow net sale product dollar million pharmaceutical plavix avaproavalide pravachol reyataz sustiva franchise total revenue baraclude erbitux taxol sprycel ixempra abilify orencia pharmaceutical total pharmaceutical nutritional enfamil nutritional total nutritional total company capital expenditure depreciation follow capital expenditure depreciation dollar million pharmaceutical nutritional total segment corporateother total corporateother amount include activity convatec medical imaging business include capital expenditure million million million depreciation expense million million million annual report company select geographic area information follow net sale yearend asset dollar millions united states europe middle east africa western hemisphere pacific total note lease minimum rental commitment noncancelable operating lease primarily real estate motor vehicle effect december follow year end december dollar million later year total minimum payment total minimum sublease rental net minimum rental commitment operate lease rental expense million million million net sublease rental income million million million february company complete sale leaseback administrative facility paris france million million result pretax gain transaction million million defer reduce future lease rental cost lease period year december company complete sale leaseback administrative facility new jersey million result pretax gain transaction million million defer reduce future lease rental cost lease period range year bristolmyer squibb note pension postretirement postemployment liability company certain subsidiary define benefit pension plan define contribution plan termination indemnity plan regular fulltime employee principal pension plan bristolmyers squibb retirement income plan represent approximately company total pension plan asset obligation fund policy contribute amount provide current service fund past service liability plan benefit base primarily participant year credit service compensation plan asset consist principally equity fixedincome security company provide comprehensive medical group life benefit substantially retiree elect participate comprehensive medical group life plan medical plan contributory contribution adjust periodically vary date retirement original retire company life insurance plan noncontributory plan asset consist principally equity fixedincome security similar plan exist employee certain country outside net periodic benefit cost company define benefit pension postretirement benefit plan include follow component pension benefit benefit dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset amortization prior service costbenefit amortization net actuarial loss amortization transitional obligation net periodic benefit cost curtailment settlement special termination benefit total net periodic benefit cost total net periodic benefit cost recognize follow pension benefit benefit dollar million continue operation discontinue operation total net periodic benefit cost estimate net actuarial loss prior service cost amortize accumulate oci net periodic benefit cost dollar million pension benefit benefit amortization net actuarial loss amortization prior service costbenefit annual report change benefit obligation plan asset fund status amount recognize balance sheet year end december company define benefit postretirement benefit plan follow pension benefit benefit dollar million benefit obligation begin year service costbenefit earn year interest cost project benefit obligation plan participant contribution curtailment settlement actuarial assumption lossesgain plan amendment retiree drug subsidy receive benefit pay special termination benefit exchange rate gainslosse benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution plan participant contribution settlement retiree drug subsidy receive benefit pay exchange rate lossesgain fair value plan asset end year fund status amount recognize consolidated balance sheet consist asset accrue expense pension postretirement liability accrue benefit cost net recognize amount recognize accumulate comprehensive loss net actuarial loss net obligation adoption prior service costbenefit net recognize impact medicare prescription drug improvement modernization act million million million reflect reduction accumulate postretirement benefit obligation accumulate benefit obligation define benefit pension plan million million december respectively information relate company pension plan december follow dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset bristolmyers squibb actuarial assumption weightedaverage assumption determine benefit obligation december follow pension benefit benefit discount rate rate compensation increase weightedaverage actuarial assumption determine net periodic benefit cost year end december follow pension benefit benefit discount rate expect longterm return plan asset rate compensation increase company use yield high quality corporate bond match duration benefit obligation determine discount rate citigroup median yield curve develop discount rate plan company consider factor develop expect return plan asset longterm historical return input external advisor individual asset class return forecast develop base market condition example price earning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class longterm expect rate return plan asset plan include active management premium approximately project market return receive external advisor company longterm expect annualize return pension plan follow year year year expect return plan asset determine expect rate return calculate value asset refer marketrelated value marketrelate value exceed fair value plan asset approximately billion december fair value plan asset approximately million december change primarily drive significant loss incur plan asset current market condition difference assume actual return amortize marketrelated value straightline basis year period gain loss result change actuarial assumption change discount rate difference assume actual experience difference actual assume return plan asset gain loss difference amortize marketrelated value amortize extent exceed high marketrelated value project benefit obligation respective plan result approximately billion related pension benefit expect amortized remain actuarial loss amortize expect remain service period active participant assume health care cost trend rate december follow health care cost trend rate assume year rate cost trend rate assume decline ultimate trend rate year rate reach ultimate trend rate annual report assume health care cost trend rate effect amount report health care plan onepercentagepoint change assume health care cost trend rate follow effect percentage percentagepoint dollar million point increase decrease effect total service interest cost effect postretirement benefit obligation plan asset company asset allocation december follow pension benefit benefit publicly trade equity security debt security include cash private equity total company investment strategy emphasize equity order achieve high expect return long run low expense low require cash contribution pension plan target asset allocation public equity international private equity fix income maintain cash flow ie cash contribution benefit payment rebalance target necessary investment diversify major asset category approximately equity investment actively manage investment strategy international pension plan typically similar asset allocation usually conservative private equity value month lag bristolmyers squibb company common stock represent plan asset december contribution contribution pension plan million million million contribution pension plan expect approximately million million contribute january contribution international pension plan million million million contribution international plan expect range million million estimate future benefit payment follow benefit payment mainly pension plan reflect expect future service appropriate expect pay benefit medicare dollar million pension benefit gross subsidy net year bristolmyer squibb adoption sfas company adopt sfas employer account define benefit pension postretirement plansan amendment fasb statement r year end december result million reduction accumulate oci stockholder equity million reduction total asset million increase total liability impact adoption summarize follow sfas adjustment dollar million presfas pretax tax net postsfas current asset defer income taxis noncurrent asset defer income taxis prepay pension asset current liability accrue expense foreign income taxis payable noncurrent liability liabilitie stockholders equity accumulate comprehensive loss saving plan principal define contribution plan bristolmyer squibb saving investment program company contribution base employee contribution level company match company contribution plan million million million post employment benefit plan company offer longterm disability benefit certain employee post employment liability million million december respectively expense relate benefit million million million termination indemnity plan company operate certain jurisdiction primarily europe require record statutory termination obligation obligation recognize undiscounted basis assume employee termination measurement date total pension liability record obligation million december million december annual report note legal proceeding contingency lawsuit claim proceeding investigation pende involve company certain subsidiary accordance sfas accounting contingency company record accrual contingency probable liability incur loss reasonably estimate matter involve antitrust security patent infringement pricing sale marketing practice environmental health safety matter consumer fraud employment matter product liability insurance coverage significant litigation charge million million million net revise estimate previously accrue amount cash payment relate significant litigation million million million significant matter describe assurance increase scope pende matter future lawsuit claim proceeding investigation material intellectual property plavix litigation plavix currently company large product rank net sale plavix patent subject number challenge include litigation apotex inc apotex corp apotex describe significant market product possible reasonably estimate impact lawsuit company loss market exclusivity plavix sustain generic competition material company sale plavix result operation cash flow material company financial condition liquidity company product partner sanofi company intend vigorously pursue enforcement patent right plavix plavix litigation patent infringement litigation apotex relate matter previously disclose company territory partnership alliance sanofi plaintiff pende patent infringement lawsuit institute united states district court southern district new york district court entitle sanofi synthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership v apotex suit base patent patent composition matter patent disclose claim thing hydrogen sulfate salt clopidogrel medicine available company plavix previously report district court uphold validity enforceability patent maintain main patent protection plavix november district court rule apotexs generic clopidogrel bisulfate product infringe patent permanently enjoin apotex engage activity infringe patent include market generic product patent expire apotex appeal district court decision december united states court appeal federal circuit circuit court affirm district court rule sustain validity patent apotex file petition circuit court rehear en banc petition pende district court stay certain antitrust counterclaim bring apotex pende final outcome appeal previously disclose company territory partnership alliance sanofi plaintiff additional pende patent infringement lawsuit dr reddys laboratories inc dr reddys laboratories ltd dr reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt watson pharmaceuticals inc watson laboratories inc watson sun pharmaceuticals sun lawsuit dr reddys teva cobalt relate patent trial date action dr reddys set january court enter order require dr reddys company business day notice intent launch patent infringement action teva cobalt stay pende resolution apotex litigation party action agree bind outcome litigation apotex teva cobalt appeal outcome litigation consequently july district court enter judgment cobalt teva permanently enjoin cobalt teva engage activity infringe patent patent expire cobalt teva file appeal lawsuit watson file october base patent patent disclose claim particular crystalline polymorph form hydrogen sulfate salt clopidogrel market plavix december court permit watson pursue declaratory judgment counterclaim respect patent january court approve party stipulation stay case pende outcome trial apotex matter april pharmastar file request inter part reexamination patent patent trademark office grant request july patent currently reexamination lawsuit sun file july base infringement patent patent respect patent sun bristolmyers squibb agree bind outcome apotex litigation sun like teva cobalt appeal outcome litigation dr reddys teva cobalt watson sun file anda fda exclusivity period statutory stay periods hatchwaxman act expire accordingly final approval fda provide company authorization distribute generic clopidogrel bisulfate product subject legal remedy company apply include injunctive relief damage previously disclose march company serve civil investigative demand ftc request document information relate propose settlement company ftc currently discussion potential resolution matter addition previously disclose april company receive subpoena new york state attorney general office antitrust bureau nyag document relate propose settlement december company enter settlement agreement nyag behalf state pursuant company agree pay million resolve state claim possible time reasonably assess outcome appeal apotex circuit court decision plavix patent litigation timing renew generic competition plavix apotex additional generic competition plavix thirdparty generic pharmaceutical company apotex prevail appeal patent litigation company expect face renew generic competition plavix promptly loss market exclusivity plavix andor sustain generic competition material company sale plavix result operation cash flow material company financial condition liquidity additionally possible time reasonably assess damage recover company apotexs ability pay damage event company prevail apotexs appeal district court decision additionally november apotex file lawsuit new jersey superior court entitle apotex inc et al v sanofiaventis et al seek payment million plus interest relate breakup propose settlement agreement december defendant remove case federal district court new jersey apotex move remand case state court plavix litigation international plavix canada apotex inc previously disclose sanofisynthelabo sanofisynthelabo canada inc institute prohibition action federal court canada apotex minister health response notice allegation noa apotex direct canadian patent patent cover clopidogrel bisulfate apotexs noa indicate file abbreviate new drug submission ands clopidogrel bisulfate tablet seek approval notice compliance and expiration patent schedule august apotexs noa allege patent invalid infringe march canadian federal court ottawa reject apotexs challenge canadian plavix patent hold asserted claim novel obvious infringe grant sanofis application order prohibition minister health apotex order prohibition preclude approval apotexs ands patent expire federal court decision reverse appeal apotex file appeal december federal court appeal dismiss apotexs appeal uphold federal court issuance order prohibition february apotex file leave appeal decision supreme court canada grant july biotecanada canadian generic pharmaceutical association canadas researchbase pharmaceutical company grant leave intervene november supreme court canada dismiss apotexs appeal federal court appeal decision uphold validity patent order prohibition previously disclose april apotex file lawsuit canada ontario superior court justice entitle apotex inc et al v sanofiaventis et al seek payment million plus interest relate breakup propose settlement agreement january court grant defendant motion dismiss ground forum non convenien subject matter jurisdiction apotex appeal decision court appeal ontario october court appeal dismiss lawsuit apotex appeal supreme court canada instead november apotex file lawsuit new jersey superior court describe plavix canada cobalt previously disclose sanofi sanofisynthelabo canada institute prohibition action federal court canada cobalt minister health response noa cobalt direct patent canadian patent patent cobalt noa indicate file ands clopidogrel bisulfate tablet seek notice compliance and expiration patent cobalt allege patent invalid patent invalid infringe follow supreme court canada decision apotex inc v sanofisynthelabo canada annual report inc scc dismiss apotexs appeal uphold validity patent describe federal court canada grant sanofis application order prohibition minister health cobalt preclude approval cobalt and patent expire sanofi pursue prohibition action respect patent plavix korea previously disclose june korean intellectual property tribunal kipt invalidate claim sanofis korean patent include claim direct clopidogrel pharmaceutically acceptable salt clopidogrel bisulfate sanofi appeal january patent court affirm kipt decision company sanofi file appeal supreme court korea sanofi commence infringement action generic pharmaceutical company launch generic clopidogrel bisulfate receive approval alternate salt form clopidogrel korea possible time reasonably assess outcome lawsuit impact company plavix australia previously disclose sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate mg tablets australia genrx subsidiary apotex change apotex august apotex file application federal court australia seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september australian court grant sanofis injunction subsidiary company subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidate apotex case trial occur april august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid view decision possible generic company develop seek registration australia alternate salt form clopidogrel bisulfate hydrochloride hydrobromide taurocholate company sanofi file notice appeal court federal court australia appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim stay federal court rule apotex file notice appeal appeal hold validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claim hearing appeal occur february decision pende plavix germany previously disclose yes pharmaceutical development service gmbh yes pharmaceutical file application marketing authorization germany alternate salt form clopidogrel application rely datum study originally conduct sanofi bms plavix german health authority bfarm grant marketing authorization yes pharmaceutical product datum protection plavix expire july sanofi bms file objection grant marketing authorization ground datum exclusivity right infringe yes pharmaceutical partner seek immediate enforcement marketing authorization deny bfarm yes pharmaceutical partner file legal motion immediate enforcement administrative court grant yes pharmaceutical partner hexal ratiopharm begin continue market product germany sanofi bms appeal decision administrative court appeal reject administrative appeal court party objection bfarm dismiss bfarm sanofi bms appeal decision administrative court cologne matter currently pende yes pharmaceutical partner announce plan seek marketing authorization eu country addition germany company believe company file approval eu clopidogrel contain product application pende intellectual property litigation abilify previously disclose otsuka file patent infringement action teva barr pharmaceuticals inc barr sandoz inc sandoz synthon laboratories inc synthon sun pharmaceuticals sun apotex relate patent cover aripiprazole expire october aripiprazole comarketed company otsuka abilify lawsuit currently pende district court district new jersey possible time reasonably assess outcome lawsuit impact company bristolmyers squibb erbitux previously disclose february abbott laboratories abbott file suit imclone district court district massachusetts allege imclone manufacture sale erbitux infringe patent patent seek damage allege infringement pursuant settlement sublicense agreement execute imclone repligen corporation repligen announce september repligen grant imclone royaltyfree irrevocable worldwide sublicense future use patent technology include patent own abbott license repligen agreement abbott repligen september imclone abbott execute write settlement agreement end litigation pende party term settlement agreement imclone pay abbott million final settlement claim counterclaim companys commercial agreement imclone include provision pursuant certain financial consequence company result settlement sublicense agreement responsibility imclone possible time assess outcome lawsuit potential impact company enfamil september company whollyowne subsidiary mead johnson co file patent infringement lawsuit abbott laboratories abbott nutrition abbott district court southern district indiana infringement patent company allege abbotts sale certain can similac infant formula powder infringe patent february company enter settlement agreement resolve matter general commercial litigation clayworth litigation previously disclose company number pharmaceutical manufacturer name defendant action file california state superior court oakland james clayworth et al v bristolmyers squibb company et al allege defendant conspire fix price pharmaceutical agree charge drug charge outside particularly canada assert claim california cartwright act unfair competition law plaintiff sought treble monetary damage injunctive relief relief december court grant company manufacturer motion summary judgment base passon defense judgment enter favor defendant july judgment favor defendant affirm california court appeals november california supreme court grant plaintiff petition review possible time reasonably assess outcome lawsuit impact company event plaintiff successful appeal rxusa wholesale litigation previously disclose july complaint file drug wholesaler rxusa wholesale inc district court eastern district new york company drug manufacturer drug wholesaler officer defendant mckesson wholesale distribution industry trade group rxusa wholesale inc v alcon labs inc et al complaint allege violation federal new york antitrust law law plaintiff claim defendant allegedly engage anti competitive act result exclusion plaintiff relevant market seek million damage trebling relief company manufacturer defendant file motion dismiss case november motion remain pende court possible time reasonably estimate outcome lawsuit impact company antitrust litigation previously disclose lawsuit comprise individual suit purport class action file company district court southern district ohio western division plaintiff include pharmacy chain individually assignee certain wholesaler health welfare benefit plansfund individual resident state lawsuit allege thing purport settlement apotex patent infringement litigation violate sherman act relate law plaintiff seek thing permanent injunctive relief bar apotex settlement andor monetary damage putative class action file behalf direct purchaser consolidate caption plavix direct purchaser antitrust litigation putative class action file behalf indirect purchaser consolidate caption plavix indirect purchaser antitrust litigation amend complaint file october defendant file consolidated motion dismiss december remain pende possible time reasonably assess outcome lawsuit impact company annual report shareholder derivative action previously disclose july certain member board director current officer company name derivative action file new york state supreme court john frank v peter dolan et al donald beebout v peter dolan et al derivative action file federal district court steven w sampson v james robinson iii et al cv complaints allege breach fiduciary duty allegedly fail disclose material information relate effort settle plavix patent infringement litigation apotex plaintiff seek monetary damage behalf company contribution indemnification decision file december state court grant motion dismiss complaint frank beebout relate certain member board director dismiss complaint officer decision date august federal district court grant company motion dismiss sampson action plaintiff appeal district court decision circuit court appeal second circuit pende security litigation bristolmyers squibb co security litigation previously disclose june july putative class action complaint minneapolis firefighter relief assoc v bristol myers squibb co et al cv jean lai v bristolmyers squibb company et al file district southern district new york company company chief executive officer peter dolan chief financial officer andrew bonfield complaints allege violation security law allegedly fail disclose material information relate effort settle plavix patent infringement litigation apotex september court dismiss lai case prejudice change caption case bristolmyer squibb co security litigation appoint ontario teacher pension plan board lead plaintiff october ontario teachers pension plan board file amend complaint make similar allegation early file complaint name additional officer long name andrew bonfield defendant decision date august federal district court deny defendant motion dismiss company intend defend vigorously litigation possible time reasonably assess outcome lawsuit potential impact company pricing sale promotional practice litigation investigation awp litigation previously disclose company number pharmaceutical manufacturer defendant number private class action suit bring attorney general state action plaintiff allege defendant cause average wholesale price awps product inflate injure government program entity person reimburse prescription drug base awps company remain defendant state attorney general suit pende federal state court country previously report set class action suit arizona attorney general consolidate district court district massachusetts awp mdl court awp mdl certify class person entity pay reimburse seven company physicianadministere drug june company settle principle claim class medicare b beneficiary nationwide million plus half cost class notice maximum payment million party finalize term settlement hearing schedule preliminary approval class settlement june nonjury trial awp mdl court find company liable violation massachusetts consumer protection law respect certain oncology drug certain year award damage thousand plus interest class private thirdparty payor instruct party apply court opinion determine damage class medigap insurer august court find damage thousand plus interest class company appeal june decision court appeal circuit oral argument hear november september court awp mdl issue order certify multistate class class class possible time reasonably assess outcome litigation matter describe potential impact company bristolmyers squibb california b litigation previously disclose august county santa clara file purport class action company numerous pharmaceutical manufacturer behalf putative class city county california cover entity purchase drug pursuant b drug discount program july district court northern district california dismiss lawsuit prejudice failure state claim plaintiff appeal court appeal ninth circuit september ninth circuit reverse district court dismissal reinstate lawsuit possible time reasonably assess outcome lawsuit potential impact company product liability litigation company party product liability lawsuit addition lawsuit company face unfiled claim involve product time company believe ongoing lawsuit likely result material effect company financial result operation company aware potential unfiled claim possible time reasonably assess outcome additional lawsuit file potential impact company company certain affiliate sanofi defendant number individual lawsuit claim personal injury allegedly sustain plavix appear united states district court district new jersey nj district court nj district court order administrative termination case pende resolution potentially relate issue united state supreme court case involve prescription drug preemption defendant execute tolling agreement respect unfiled claim potential additional plaintiff possible time reasonably asse outcome lawsuit impact company environmental proceeding previously report company party environmental proceeding matter responsible state federal foreign law include comprehensive environmental response compensation liability act cercla certain cost investigate andor remediate contamination result past industrial activity company current site waste disposal reprocess facility operate party cercla matter respect cercla matter company responsible state federal foreign law company typically estimate potential cost base information obtain environmental protection agency epa counterpart state agency andor study prepare independent consultant include total estimate cost site expect cost share potentially responsible party company accrue liability probable reasonably estimable december company estimate share total future cost site approximately million record liability represent sum good estimate simple estimate reasonably estimate minimal probable range cost take account potential recovery party currently expect passaic river nj remediation natural resource damage claim previously disclose september new jersey department environmental protection njdep issue administrative enforcement directive require company company perform assessment natural resource damage implement unspecified interim remedial measure restore condition low passaic river lpr directive name company release nearby bulk chemical reprocess facility operate predecessor mckesson corp subsequently epa issue notice letter numerous party company request performance remedial investigationfeasibility study rif condition lpr consent agreement epa group party commit pay roughly half million estimate rif epa time epa substantially increase estimate scope cost rif result epa agree allow group perform remain rif task group estimate total cost complete rif relate task exceed million group negotiate amend consent agreement epa conduct remain rif work effective process company mckesson buy remain rif task annual report separately company agree pay approximately thousand rif task previously fund mckesson work cooperatively go forward subject later reallocation mid epa announce plan seek implementation earlyaction remedial measure address highlycontaminate portion lpr rif complete epa indicate expect select action early subgroup cooperate private party commence discussion federal natural resource trustee agency concern agreement assess natural resource damage lpr discussion expect continue mid remain party include company mckesson decline discuss proposal scope cost earlyaction seek epa thoroughly understand extent liability company face relate requirement determine north brunswick township board education previously disclose october company contact counsel represent north brunswick nj board education boe site waste material er squibb son disposed fill material contain industrial waste heavy metal excess residential standard discover expansion project north brunswick township high school number neighbor residential property adjacent public park area january njdep send company information request letter possible waste disposal site company respond march boe township current owner school property park conduct jointly finance soil remediation work ground water investigation work work plan approve njdep ask company contribute cost company actively monitor cleanup project include cost date school board township assert claim company instead company local entity negotiate agreement attempt resolve matter informal mean include mediation bind allocation necessary central component agreement provision company interim funding help defray cleanup cost assure work interrupt company transmit initial interim funding payment december party commence mediation activity expect conclude mid od regulatory compliance previously disclose epa investigate industrial commercial facility use refrigeration equipment contain ozonedeplete substance od enforce compliance regulation govern prevention service repair leak od requirement company perform voluntary corporatewide audit facility puerto rico use odscontaine refrigeration equipment company submit audit report epa november identify potential violation od requirement facility addition matter cover company audit report letter epa epa previously send mead johnson request information compliance od requirement facility evansville indiana company respond request june result identify potential violation evansville facility company sign consent decree epa resolve potential violation discover audit identify result epa request information evansville facility file evansville division district court southern district indiana july consent decree require company pay civil penalty thousand retire retrofit replace odscontaine refrigeration unit june locate facility new jersey indiana puerto rico consent decree require company spend thousand supplemental environmental project consist removal odscontaine comfort cool device new brunswick nj facility tie function new centralized chiller system use od refrigerant consent decree enter court new brunswick facility environmental personal injury lawsuit previously disclose approximately lawsuit file company superior court middlesex county nj behalf current resident new brunswick nj live adjacent company new brunswick facility complaint allege personal injury property damage result soil groundwater contamination property stem historical operation new brunswick facility complaint allege bms fail remediate contamination new brunswick facility compliance state federal cleanup requirement new brunswick facility undergo environmental remediation new jersey department environmental protection njdep approve cleanup plan addition lawsuit plaintiff file notice seek relief nj environmental right act october new jersey supreme court grant mass tort status case transfer new jersey superior court atlantic county centralize case management purpose company file motion dismiss lawsuit deny leave refile discovery take pende court company intend defend vigorously litigation possible time reasonably assess outcome lawsuit potential impact company bristolmyer squibb wage hour litigation previously disclose putative class action complaint file company sale representative beth amendola v bristolmyers squibb company et al docket cv file june district court plaintiff allege company violate federal fair labor standard act thing pay overtime compensation putative class similarly situate sale employee june court issue decision render case nonclass action lawsuit company settle lawsuit individual plaintiff settlement agreement material company conclude lawsuit proceeding sec germany investigation previously disclose october sec notify company conduct informal inquiry activity certain company german pharmaceutical subsidiary employee andor agent october sec inform company inquiry formal secs inquiry encompass matter currently investigation german prosecutor munich germany company understand inquiry investigation concern potential violation foreign corrupt practice act german law respectively company cooperate sec german authority company establish accrual respect investigation german prosecutor possible time reasonably assess outcome investigation impact company convatec italy investigation previously report italian competition authority investigate complaint lodge hospital ferrara region italy relate allegation medical device company include convatec boycott tender ferrara tender convatec receive statement objection italian competition authority authority allege medical device company include convatec act concert manner regard ferrara tender tender pricing discussion region act way prevent competition italy august competition authority issue decision find medical device company infringe italian antitrust law participate ferrara tender impose fine convatec material company convatec division bms italy prior divestiture fine impose bms italy convatec appeal decision administrative court fine impose convatec later reduce company appeal decision high court second instance consiglio di stato hearing occur february annual report note select quarterly financial datum unaudite dollar million share datum quarter second quarter quarter fourth quarter year net sale gross margin net earning continue operation net earning discontinue operation net net earning earning common share basic net earning continue operation net earning discontinue operation net net earning common share dilute net earning continue operation net earning discontinue operation net net earning common share dividend declare common share cash cash equivalent marketable security dollar million share datum quarter second quarter quarter fourth quarter year net sale gross margin net earningsloss continue operation net earning discontinue operation net net earningsloss earning common share basic net earningsloss continue operation net earning discontinue operation net net earningsloss common share dilute net earningsloss continue operation net earning discontinue operation net net earningsloss common share dividend declare common share cash cash equivalent marketable security earning share quarter add amount year period compute discrete basis bristolmyer squibb company record follow specify expenseincome item affect comparability result second fourth dollar million quarter quarter quarter quarter year productivity transformation initiative downsize streamline worldwide operation accelerate depreciation asset impairment shutdown cost pension settlementscurtailment process standardization implementation cost gain sale leaseback property termination lease contract gain sale product line business litigation settlement insurance recovery mead johnson charge product liability upfront milestone payment acquire inprocess research development asset impairment ar impairment charge gainloss sale debt buyback swap termination gain sale imclone share income taxis item decreaseincrease net earning continue operation second fourth dollar million quarter quarter quarter quarter year productivity transformation initiative downsize streamline worldwide operation accelerate depreciation asset impairment process standardization implementation cost litigation settlement insurance recovery product liability upfront milestone payment acquire inprocess research development ar impairment charge downsize streamline worldwide operation accelerate depreciation asset impairment contract termination gain sale property product line business income taxis item change estimate taxis prior year specify item decreaseincrease net earning continue operation annual report follow table reconcile previously report datum current year quarterly datum update discontinued operation relate convatec disposition note discontinued operation asset hold sale quarter fourth quarter quarter adjust report adjust report adjust report previously convatec december previously convatec december previously convatec december dollar million share datum report disposition k report disposition k report disposition k net sale gross margin net earning continue operation net earning discontinue operation net net earning earning common share basic net earning continue operation net earning discontinue operation net net earning common share dilute net earning continue operation net earning discontinue operation net net earning common share bristolmyer squibb report management management responsibility financial statement management responsible preparation integrity financial information present annual report accompany consolidated financial statement prepare conformity accounting principle generally accept united states america gaap apply certain estimate judgment require management opinion consolidated financial statement present fairly company financial position result operation cash flow audit committee board director meet regularly internal auditor deloitte touche llp dt company independent register accounting firm management review account internal control structure financial reporting matter internal auditor dt free access audit committee set forth company standard business conduct ethic company firmly commit adhere high standard moral ethical behavior business activity management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance accounting principle generally accept united states america gaap inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include annual report issue report management assessment effectiveness company internal control appear annual report james cornelius chairman chief executive officer jeanmarc huet chief financial officer february annual report control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure term define exchange act rule ae base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include annual report issue report effectiveness company internal control financial reporting december include change internal control financial reporting change companys internal control financial reporting quarter end december materially affect reasonably likely materially affect company internal control financial reporting information february mead johnson company mjc borrower mead johnson nutrition company mead johnson guarantor indirect majorityowne subsidiary company enter year syndicate revolve credit facility agreement credit facility financial institution lender name include jpmorgan chase bank na jpmcb administrative agent credit facility unsecured repayable maturity february subject annual extension sufficient lender agree maximum outstanding borrowing letter credit permit time credit facility million increase time time million request mjc subject customary condition contain credit facility proceed credit facility work capital general corporate purpose mead johnson subsidiary include commercial paper backup repurchase share borrowing credit facility bear interest libor rate specify interest period plus margin determine reference company consolidate leverage ratio b float rate base jpmcbs prime rate federal fund rate libor rate plus case margin determine reference company consolidate leverage ratio company pay customary facility structure syndication administration fee mead johnson guarantee obligation mjc subsidiary borrower credit facility additional subsidiary mead johnson borrower credit facility case mead johnson mjc guaranty obligation subsidiary credit facility credit facility contain customary covenant include covenant applicable mead johnson subsidiary limit lien substantial asset sale merger restriction subject certain minimum threshold exception credit facility contain follow financial covenant mead johnson require maintain ratio consolidate total debt ii consolidated ebitda great compliance covenant test day fiscal quarter condition precedent credit extension credit facility b mead johnson require maintain ratio consolidated ebitda ii consolidated interest expense compliance covenant test day fiscal quarter precede consecutive fiscal quarter addition credit facility customary event default include subject certain materiality threshold grace period payment default failure comply covenant material inaccuracy representation warranty bankruptcy insolvency proceeding change control erisa matter crossdefault debt agreement bristolmyer squibb report independent register public accounting firm board director stockholder bristolmyers squibb company audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income retain earning cash flow year period end december financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position bristolmyer squibb company subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america discuss note consolidated financial statement company adopt financial accounting standard board interpretation fin accounting uncertainty income taxis interpretation fasb statement effective january statement financial accounting standard sfas employer account define benefit pension postretirement plan amendment fasb statement r effective december audit accordance standard public company accounting oversight board united states company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting deloitte touche llp parsippany new jersey february annual report report independent register public accounting firm board director stockholder bristolmyers squibb company audit internal control financial reporting bristolmyer squibb company subsidiary company december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle company internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission audit accordance standard public company accounting oversight board united states consolidated financial statement year end december company report date february express unqualified opinion financial statement deloitte touche llp parsippany new jersey february bristolmyers squibb year financial summary amount million share datum income statement datum net sale earn continue operation income taxis minority interest net earning continue operation net earning continue operation common share basic diluted average common share outstanding basic dilute dividend pay common prefer stock dividend declare common share financial position datum december total asset cash cash equivalent marketable security longterm debt stockholder equity company record item affect comparability result discussion item year management discussion analysis financial condition result operationsexpensesgain board director james cornelius laurie h glimcher md vicki l sato phd chairman chief executive officer irene heinz give professor professor management practice bristolmyer squibb immunology harvard harvard business school school public health professor molecular cell lamberto andreotti professor medicine harvard biology harvard university cd president chief operating officer medical school abd bristolmyer squibb togo west jr michael grobstein chairman tli leadership lewis b campbell retire vice chairman group noblis inc bc lead independent director ernst young ac bristolmyers squibb r sanders williams md chairman president chief leif johansson senior vice chancellor executive officer textron inc abc president ab volvo academic affair chief executive officer duke university bd louis j freeh volvo group ac president freeh group international solution llc managing partner alan j lacy audit committee freeh sullivan sporkin llp ab senior advisor oak hill b committee director corporate governance capital partner lp ab c compensation management development committee science technology committee management council james cornelius brian daniels md anthony mcbride phd chairman senior vice president senior vice president chief executive officer global development medical human resource affair research development lamberto andreotti elliott sigal md phd president carlo de notaristefani cirm executive vice president chief operating officer president technical operation chief scientific officer global support function president batrice cazala research development president global commercialization anthony c hooper president europe president americas robert zito senior vice president john e celentano jeanmarc huet corporate business president emerge market executive vice president communications asia pacific chief financial officer chief communication officer sandra leung senior vice president general counsel corporate secretary executive committee member stockholder information common stock product name company program ticker symbol bmy new york free copy company annual product name company program stock exchange report fiscal year appear italic end december contact trademark bristolmyers squibb annual meeting stockholder secretary company division tuesday bristolmyer squibb company subsidiary company global product refer register bristolmyers squibb company park avenue approve trademark scudder mill road new york ny specifically note plainsboro nj available abilify trademark stockholder service program wwwbmscominvestor otsuka pharmaceutical co ltd inquiry concern stockholder account stock transfer matter recent certification atripla trademark include address change elim company chief executive officer bristolmyers squibb ination duplicate mailing chief financial officer pursuant section gilead sciences llc investor service programshould sarbanesoxley act direct company transfer file exhibit company avapro avalide aprovel agent registrar company file karvea iscover plavix mellon investor services llc new york stock exchange trademark sanofiaventis recent annual ceo certification washington boulevard bufferin excedrin japan require section aa jersey city nj asia exclude china taiwan new york stock exchange list certain oceanic country wwwmelloninvestorcomisd company manual trademark lion corporation information follow subject dovonex trademark outside available wwwbmscom leo pharma tdd telephone service bristolmyer squibb foundation hearingimpaire enfamil trademark sustainabilityenvironmental programs mead johnson company political contribution outside erbitux trademark diversity eeo report eli lilly company investor service program investor service program design annual report contain certain gleevec trademark longterm investor wish build forwardlooke information novartis ag mean private security litigation share ownership company com similac trademark reform act forwardlook mon stock time participate abbott laboratories ing statement involve substantial risk program register holder company common stock uncertainty cause truvada trademark company com actual result differ materially gilead sciences inc expectation estimate reflect mon stock participant forwardlooke statement make initial purchase directly financial review program program discussion description risk feature dividend reinvestment optional uncertainty company cash purchase share safekeeping take obligation publicly update share sale transfer bristolmyer forwardlooke statement squibb appoint mellon bank na result new information future administrator program event program sponsor administer bristolmyer squibb company bristolmyers squibb annual reporton right age sandra ragan jacksonville florida feel tired usual doctor tell type diabetes ve get diabete family say shock diagnosis doctor recommend diet exercise enrol clinical trial dapagliflozin investigational compound discover bristolmyer squibb scientist dapagliflozin develop collaboration astrazeneca treatment type diabetes chronic disease occur body produce insulin use insulin produce world health organization estimate million people worldwide diabete type dia bete call noninsulindependent adultonset repre sent percent diabete case follow doctor recommendation sandra feel well energy pick thing need include spend time daughter grandchild picture right sandra grandchild danielle pacie cover kevin sharp go let diagnosis cancer way dream country songwriter recording artist dream sustain year treatment age kevin living dream platinum debut album string hit cancer remain remission kevin prevail disease wwwbmscom copyright bristolmyers squibb company right reserve produce bristolmyer squibb communication departmenttogether prevail park avenue new york ny wwwbmscom